

REFERENCES

- Adamson, C.S. and Freed, E.O. (2008) Recent progress in antiretrovirals--lessons from resistance. *Drug Discov Today* 13, 424-32.
- Agosto, L.M., Yu, J.J., Dai, J., Kaletsky, R., Monie, D. and O'Doherty, U. (2007) HIV-1 integrates into resting CD4⁺ T cells even at low inoculums as demonstrated with an improved assay for HIV-1 integration. *Virology* 368, 60-72.
- Aldrovandi, G.M. and Zack, J.A. (1996) Replication and pathogenicity of human immunodeficiency virus type 1 accessory gene mutants in SCID-hu mice. *J Virol* 70, 1505-11.
- Amado, R.G. and Chen, I.S. (1999) Lentiviral vectors--the promise of gene therapy within reach? *Science* 285, 674-6.
- Balakrishnan, M. and Jonsson, C.B. (1997) Functional identification of nucleotides conferring substrate specificity to retroviral integrase reactions. *J Virol* 71, 1025-35.
- Baltimore, D. (1970) RNA-dependent DNA polymerase in virions of RNA tumour viruses. *Nature* 226, 1209-11.
- Barbosa, P., Charneau, P., Dumey, N. and Clavel, F. (1994) Kinetic analysis of HIV-1 early replicative steps in a coculture system. *AIDS Res Hum Retroviruses* 10, 53-9.
- Bartsevich, V.V., Miller, J.C., Case, C.C. and Pabo, C.O. (2003) Engineered zinc finger proteins for controlling stem cell fate. *Stem Cells* 21, 632-7.

- Beerli, R.R., Segal, D.J., Dreier, B. and Barbas, C.F., 3rd. (1998) Toward controlling gene expression at will: specific regulation of the erbB-2/HER-2 promoter by using polydactyl zinc finger proteins constructed from modular building blocks. *Proc Natl Acad Sci U S A* 95, 14628-33.
- Blancafort, P., Segal, D.J. and Barbas, C.F., 3rd. (2004) Designing transcription factor architectures for drug discovery. *Mol Pharmacol* 66, 1361-71.
- Bohjanen, P.R., Colvin, R.A., Puttaraju, M., Been, M.D. and Garcia-Blanco, M.A. (1996) A small circular TAR RNA decoy specifically inhibits Tat-activated HIV-1 transcription. *Nucleic Acids Res* 24, 3733-8.
- BouHamdan, M., Duan, L.X., Pomerantz, R.J. and Strayer, D.S. (1999) Inhibition of HIV-1 by an anti-integrase single-chain variable fragment (SFv): delivery by SV40 provides durable protection against HIV-1 and does not require selection. *Gene Ther* 6, 660-6.
- Brown, P.O. (1990) Integration of retroviral DNA. *Curr Top Microbiol Immunol* 157, 19-48.
- Brown, R.S. (2005) Zinc finger proteins: getting a grip on RNA. *Curr Opin Struct Biol* 15, 94-8.
- Bugreev, D.V., Baranova, S., Zakharova, O.D., Parissi, V., Desjobert, C., Sottofattori, E., Balbi, A., Litvak, S., Tarrago-Litvak, L. and Nevinsky, G.A. (2003) Dynamic, thermodynamic, and kinetic basis for recognition and transformation of DNA by human immunodeficiency virus type 1 integrase. *Biochemistry* 42, 9235-47.

- Bukrinsky, M.I., Haggerty, S., Dempsey, M.P., Sharova, N., Adzhubel, A., Spitz, L., Lewis, P., Goldfarb, D., Emerman, M. and Stevenson, M. (1993) A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. *Nature* 365, 666-9.
- Bushman, F.D. and Craigie, R. (1991) Activities of human immunodeficiency virus (HIV) integration protein in vitro: specific cleavage and integration of HIV DNA. *Proc Natl Acad Sci U S A* 88, 1339-43.
- Bushman, F.D., Engelman, A., Palmer, I., Wingfield, P. and Craigie, R. (1993) Domains of the integrase protein of human immunodeficiency virus type 1 responsible for polynucleotidyl transfer and zinc binding. *Proc Natl Acad Sci U S A* 90, 3428-32.
- Butler, S.L., Hansen, M.S. and Bushman, F.D. (2001) A quantitative assay for HIV DNA integration in vivo. *Nat Med* 7, 631-4.
- Butler, S.L., Johnson, E.P. and Bushman, F.D. (2002) Human immunodeficiency virus cDNA metabolism: notable stability of two-long terminal repeat circles. *J Virol* 76, 3739-47.
- Cai, M., Zheng, R., Caffrey, M., Craigie, R., Clore, G.M. and Gronenborn, A.M. (1997) Solution structure of the N-terminal zinc binding domain of HIV-1 integrase. *Nat Struct Biol* 4, 567-77.
- Cavert, W., Notermans, D.W., Staskus, K., Wietgreffe, S.W., Zupancic, M., Gebhard, K., Henry, K., Zhang, Z.Q., Mills, R., McDade, H., Schuwirth, C.M., Goudsmit, J., Danner, S.A. and Haase, A.T. (1997) Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. *Science* 276, 960-4.

- Chan, D.C., Fass, D., Berger, J.M. and Kim, P.S. (1997) Core structure of gp41 from the HIV envelope glycoprotein. *Cell* 89, 263-73.
- Charpentier, C., Karmochkine, M., Laureillard, D., Tisserand, P., Belec, L., Weiss, L., Si-Mohamed, A. and Piketty, C. (2008) Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy. *HIV Med* 9, 765-70.
- Chen, L.F., Hoy, J. and Lewin, S.R. (2007) Ten years of highly active antiretroviral therapy for HIV infection. *Med J Aust* 186, 146-51.
- Chiu, T.K. and Davies, D.R. (2004) Structure and function of HIV-1 integrase. *Curr Top Med Chem* 4, 965-77.
- Choo, Y. and Klug, A. (1994) Toward a code for the interactions of zinc fingers with DNA: selection of randomized fingers displayed on phage. *Proc Natl Acad Sci U S A* 91, 11163-7.
- Choo, Y., Sanchez-Garcia, I. and Klug, A. (1994) In vivo repression by a site-specific DNA-binding protein designed against an oncogenic sequence. *Nature* 372, 642-5.
- Christy, B. and Nathans, D. (1989) DNA binding site of the growth factor-inducible protein Zif268. *Proc Natl Acad Sci U S A* 86, 8737-41.
- Chun, T.W., Carruth, L., Finzi, D., Shen, X., DiGiuseppe, J.A., Taylor, H., Hermankova, M., Chadwick, K., Margolick, J., Quinn, T.C., Kuo, Y.H., Brookmeyer, R., Zeiger, M.A., Barditch-Crovo, P. and Siliciano, R.F. (1997) Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. *Nature* 387, 183-8.

- Chun, T.W., Finzi, D., Margolick, J., Chadwick, K., Schwartz, D. and Siliciano, R.F. (1995) In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. *Nat Med* 1, 1284-90.
- Cimarelli, A. and Darlix, J.L. (2002) Assembling the human immunodeficiency virus type 1. *Cell Mol Life Sci* 59, 1166-84.
- Clapham, P.R. and McKnight, A. (2002) Cell surface receptors, virus entry and tropism of primate lentiviruses. *J Gen Virol* 83, 1809-29.
- Coffin, J.M. (1995) HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. *Science* 267, 483-9.
- Coffin JM, Hughes SH, Varmus HE, (1997) *Retroviruses* [online]. Cold Spring Harbor Laboratory Press. Available: <http://www.ncbi.nlm.nih.gov/books/NBK19418/>. (2011, March 9).
- Cohli, H., Fan, B., Joshi, R.L., Ramezani, A., Li, X. and Joshi, S. (1994) Inhibition of HIV-1 multiplication in a human CD4⁺ lymphocytic cell line expressing antisense and sense RNA molecules containing HIV-1 packaging signal and Rev response element(s). *Antisense Res Dev* 4, 19-26.
- De Clercq, E. (2001) New developments in anti-HIV chemotherapy. *Curr Med Chem* 8, 1543-72.
- Deeks, S.G. (2011) HIV infection, inflammation, immunosenescence, and aging. *Annu Rev Med* 62, 141-55.
- Delelis, O., Malet, I., Na, L., Tchertanov, L., Calvez, V., Marcelin, A.G., Subra, F., Deprez, E. and Mouscadet, J.F. (2009) The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. *Nucleic Acids Res* 37, 1193-201.

- Demirov, D.G. and Freed, E.O. (2004) Retrovirus budding. *Virus Res* 106, 87-102.
- Deprez, E., Barbe, S., Kolaski, M., Leh, H., Zouhiri, F., Auclair, C., Brochon, J.C., Le Bret, M. and Mouscadet, J.F. (2004) Mechanism of HIV-1 integrase inhibition by styrylquinoline derivatives in vitro. *Mol Pharmacol* 65, 85-98.
- Dimauro, S., Mancuso, M. and Naini, A. (2004) Mitochondrial encephalomyopathies: therapeutic approach. *Ann N Y Acad Sci* 1011, 232-45.
- Donehower, L.A. and Varmus, H.E. (1984) A mutant murine leukemia virus with a single missense codon in pol is defective in a function affecting integration. *Proc Natl Acad Sci U S A* 81, 6461-5.
- Dreier, B., Beerli, R.R., Segal, D.J., Flippin, J.D. and Barbas, C.F., 3rd. (2001) Development of zinc finger domains for recognition of the 5'-ANN-3' family of DNA sequences and their use in the construction of artificial transcription factors. *J Biol Chem* 276, 29466-78.
- Dreier, B., Fuller, R.P., Segal, D.J., Lund, C.V., Blancafort, P., Huber, A., Koksche, B. and Barbas, C.F., 3rd. (2005) Development of zinc finger domains for recognition of the 5'-CNN-3' family DNA sequences and their use in the construction of artificial transcription factors. *J Biol Chem* 280, 35588-97.
- Dreier, B., Segal, D.J. and Barbas, C.F., 3rd. (2000) Insights into the molecular recognition of the 5'-GNN-3' family of DNA sequences by zinc finger domains. *J Mol Biol* 303, 489-502.
- Drelich, M., Wilhelm, R. and Mous, J. (1992) Identification of amino acid residues critical for endonuclease and integration activities of HIV-1 IN protein in vitro. *Virology* 188, 459-68.

- Dull, T., Zufferey, R., Kelly, M., Mandel, R.J., Nguyen, M., Trono, D. and Naldini, L. (1998) A third-generation lentivirus vector with a conditional packaging system. *J Virol* 72, 8463-71.
- Eckert, D.M. and Kim, P.S. (2001) Mechanisms of viral membrane fusion and its inhibition. *Annu Rev Biochem* 70, 777-810.
- Engelman, A., Bushman, F.D. and Craigie, R. (1993) Identification of discrete functional domains of HIV-1 integrase and their organization within an active multimeric complex. *EMBO J* 12, 3269-75.
- Esposito, D. and Craigie, R. (1999) HIV integrase structure and function. *Adv Virus Res* 52, 319-33.
- Evering, T.H. and Markowitz, M. (2008) Raltegravir: an integrase inhibitor for HIV-1. *Expert Opin Investig Drugs* 17, 413-22.
- Faure, A., Calmels, C., Desjobert, C., Castroviejo, M., Caumont-Sarcos, A., Tarrago-Litvak, L., Litvak, S. and Parissi, V. (2005) HIV-1 integrase crosslinked oligomers are active in vitro. *Nucleic Acids Res* 33, 977-86.
- Flexner, C. (2007) HIV drug development: the next 25 years. *Nat Rev Drug Discov* 6, 959-66.
- Frankel, A.D. and Young, J.A. (1998) HIV-1: fifteen proteins and an RNA. *Annu Rev Biochem* 67, 1-25.
- Freed, E.O. (2001) HIV-1 replication. *Somat Cell Mol Genet* 26, 13-33.
- Gallay, P., Hope, T., Chin, D. and Trono, D. (1997) HIV-1 infection of nondividing cells through the recognition of integrase by the importin/karyopherin pathway. *Proc Natl Acad Sci U S A* 94, 9825-30.

- Ganser-Pornillos, B.K., Yeager, M. and Sundquist, W.I. (2008) The structural biology of HIV assembly. *Curr Opin Struct Biol* 18, 203-17.
- Goncalves, J., Silva, F., Freitas-Vieira, A., Santa-Marta, M., Malho, R., Yang, X., Gabuzda, D. and Barbas, C., 3rd. (2002) Functional neutralization of HIV-1 Vif protein by intracellular immunization inhibits reverse transcription and viral replication. *J Biol Chem* 277, 32036-45.
- Gonzalez, B., Schwimmer, L.J., Fuller, R.P., Ye, Y., Asawapornmongkol, L. and Barbas, C.F., 3rd. (2010) Modular system for the construction of zinc-finger libraries and proteins. *Nat Protoc* 5, 791-810.
- Gotte, M., Li, X. and Wainberg, M.A. (1999) HIV-1 reverse transcription: a brief overview focused on structure-function relationships among molecules involved in initiation of the reaction. *Arch Biochem Biophys* 365, 199-210.
- Grant, P. and Zolopa, A. (2008) Integrase inhibitors: a clinical review of raltegravir and elvitegravir. *J HIV Ther* 13, 36-9.
- Greenberg, K.P., Lee, E.S., Schaffer, D.V. and Flannery, J.G. (2006) Gene delivery to the retina using lentiviral vectors. *Adv Exp Med Biol* 572, 255-66.
- Greisman, H.A. and Pabo, C.O. (1997) A general strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites. *Science* 275, 657-61.
- Grote, A., Hiller, K., Scheer, M., Munch, R., Nortemann, B., Hempel, D.C. and Jahn, D. (2005) JCat: a novel tool to adapt codon usage of a target gene to its potential expression host. *Nucleic Acids Res* 33, W526-31.
- Gupta, R.K. and Pillay, D. (2007) HIV resistance and the developing world. *Int J Antimicrob Agents* 29, 510-7.

- Hahn, B.H., Shaw, G.M., Arya, S.K., Popovic, M., Gallo, R.C. and Wong-Staal, F. (1984) Molecular cloning and characterization of the HTLV-III virus associated with AIDS. *Nature* 312, 166-9.
- Han, Y., Lassen, K., Monie, D., Sedaghat, A.R., Shimoji, S., Liu, X., Pierson, T.C., Margolick, J.B., Siliciano, R.F. and Siliciano, J.D. (2004) Resting CD4⁺ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. *J Virol* 78, 6122-33.
- Haynes, B.F., Pantaleo, G. and Fauci, A.S. (1996) Toward an understanding of the correlates of protective immunity to HIV infection. *Science* 271, 324-8.
- Hazuda, D.J. (2010) Resistance to inhibitors of the human immunodeficiency virus type 1 integration. *Braz J Infect Dis* 14, 513-8.
- Hazuda, D.J., Felock, P., Witmer, M., Wolfe, A., Stillmock, K., Grobler, J.A., Espeseth, A., Gabryelski, L., Schleif, W., Blau, C. and Miller, M.D. (2000) Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. *Science* 287, 646-50.
- Hicks, C., Gulick, R.M., Roquebert, B., Blum, L., Collin, G., Damond, F., Peytavin, G., Leleu, J., Matheron, S., Chene, G., Brun-Vezinet, F. and Descamps, D. (2009) Raltegravir: the first HIV type 1 integrase inhibitor Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen. *Clin Infect Dis* 48, 931-9.
- Isalan, M., Klug, A. and Choo, Y. (2001) A rapid, generally applicable method to engineer zinc fingers illustrated by targeting the HIV-1 promoter. *Nat Biotechnol* 19, 656-60.

- Jamieson, A.C., Kim, S.H. and Wells, J.A. (1994) In vitro selection of zinc fingers with altered DNA-binding specificity. *Biochemistry* 33, 5689-95.
- Jelinek, W.R. and Schmid, C.W. (1982) Repetitive sequences in eukaryotic DNA and their expression. *Annu Rev Biochem* 51, 813-44.
- Jenkins, T.M., Engelman, A., Ghirlando, R. and Craigie, R. (1996) A soluble active mutant of HIV-1 integrase: involvement of both the core and carboxyl-terminal domains in multimerization. *J Biol Chem* 271, 7712-8.
- Jonsson, C.B., Donzella, G.A., Gaucan, E., Smith, C.M. and Roth, M.J. (1996) Functional domains of Moloney murine leukemia virus integrase defined by mutation and complementation analysis. *J Virol* 70, 4585-97.
- Jurriaans, S., de Ronde, A., Dekker, J., Goudsmit, J. and Cornelissen, M. (1992) Analysis of human immunodeficiency virus type 1 LTR-LTR junctions in peripheral blood mononuclear cells of infected individuals. *J Gen Virol* 73 (Pt 6), 1537-41.
- Kafri, T., Blomer, U., Peterson, D.A., Gage, F.H. and Verma, I.M. (1997) Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. *Nat Genet* 17, 314-7.
- Katz, R.A. and Skalka, A.M. (1994) The retroviral enzymes. *Annu Rev Biochem* 63, 133-73.
- Katzman, M. and Sudol, M. (1996) Influence of subterminal viral DNA nucleotides on differential susceptibility to cleavage by human immunodeficiency virus type 1 and visna virus integrases. *J Virol* 70, 9069-73.

- Kelly, J., Beddall, M.H., Yu, D., Iyer, S.R., Marsh, J.W. and Wu, Y. (2008) Human macrophages support persistent transcription from unintegrated HIV-1 DNA. *Virology* 372, 300-12.
- Killebrew, D.A., Troelstrup, D. and Shiramizu, B. (2004) Preferential HIV-1 integration sites in macrophages and HIV-associated malignancies. *Cell Mol Biol (Noisy-le-grand)* 50 Online Pub, OL581-9.
- Kim, S.Y., Byrn, R., Groopman, J. and Baltimore, D. (1989) Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression. *J Virol* 63, 3708-13.
- Koelsch, K.K., Liu, L., Haubrich, R., May, S., Havlir, D., Gunthard, H.F., Ignacio, C.C., Campos-Soto, P., Little, S.J., Shafer, R., Robbins, G.K., D'Aquila, R.T., Kawano, Y., Young, K., Dao, P., Spina, C.A., Richman, D.D. and Wong, J.K. (2008) Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. *J Infect Dis* 197, 411-9.
- LaFemina, R.L., Callahan, P.L. and Cordingley, M.G. (1991) Substrate specificity of recombinant human immunodeficiency virus integrase protein. *J Virol* 65, 5624-30.
- Lanao, J.M., Briones, E. and Colino, C.I. (2007) Recent advances in delivery systems for anti-HIV1 therapy. *J Drug Target* 15, 21-36.
- Le Rouzic, E. and Benichou, S. (2005) The Vpr protein from HIV-1: distinct roles along the viral life cycle. *Retrovirology* 2, 11.
- Lee, M.S., Gippert, G.P., Soman, K.V., Case, D.A. and Wright, P.E. (1989) Three-dimensional solution structure of a single zinc finger DNA-binding domain. *Science* 245, 635-7.

- Lee, N.S., Dohjima, T., Bauer, G., Li, H., Li, M.J., Ehsani, A., Salvaterra, P. and Rossi, J. (2002) Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. *Nat Biotechnol* 20, 500-5.
- Lehrman, G., Hogue, I.B., Palmer, S., Jennings, C., Spina, C.A., Wiegand, A., Landay, A.L., Coombs, R.W., Richman, D.D., Mellors, J.W., Coffin, J.M., Bosch, R.J. and Margolis, D.M. (2005) Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. *Lancet* 366, 549-55.
- Levy-Mintz, P., Duan, L., Zhang, H., Hu, B., Dornadula, G., Zhu, M., Kulkosky, J., Bizub-Bender, D., Skalka, A.M. and Pomerantz, R.J. (1996) Intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle by targeting human immunodeficiency virus type 1 integrase. *J Virol* 70, 8821-32.
- Levy, J.A. (2007) HIV and the pathogenesis of AIDS. [Online] Available: http://books.google.co.th/books?id=ii-pri5nWakC&pg=PA77&lpg=PA77&dq=non-covalent+circular+HIV+DNA+pathogenesis&source=bl&ots=ao1M013cz-&sig=tcxHPTp5Zq4wOAJM1INyXvJnW4s&hl=th&ei=GkEPTrawK4XKRAfjIqmIBA&sa=X&oi=book_result&ct=result&resnum=1&ved=0CB4Q6AEwAA#v=onepage&q&f=false (2011, May 9).
- Li, Z., Dullmann, J., Schiedlmeier, B., Schmidt, M., von Kalle, C., Meyer, J., Forster, M., Stocking, C., Wahlers, A., Frank, O., Ostertag, W., Kuhlcke, K., Eckert, H.G., Fehse, B. and Baum, C. (2002) Murine leukemia induced by retroviral gene marking. *Science* 296, 497.

- Liem, S.E., Ramezani, A., Li, X. and Joshi, S. (1993) The development and testing of retroviral vectors expressing trans-dominant mutants of HIV-1 proteins to confer anti-HIV-1 resistance. *Hum Gene Ther* 4, 625-34.
- Liszewski, M.K., Yu, J.J. and O'Doherty, U. (2009) Detecting HIV-1 integration by repetitive-sampling Alu-gag PCR. *Methods* 47, 254-60.
- Liu, Q., Segal, D.J., Ghiara, J.B. and Barbas, C.F., 3rd. (1997) Design of polydactyl zinc-finger proteins for unique addressing within complex genomes. *Proc Natl Acad Sci U S A* 94, 5525-30.
- Lu, X., Yu, Q., Binder, G.K., Chen, Z., Slepushkina, T., Rossi, J. and Dropulic, B. (2004) Antisense-mediated inhibition of human immunodeficiency virus (HIV) replication by use of an HIV type 1-based vector results in severely attenuated mutants incapable of developing resistance. *J Virol* 78, 7079-88.
- Mandell, J.G. and Barbas, C.F., 3rd. (2006) Zinc Finger Tools: custom DNA-binding domains for transcription factors and nucleases. *Nucleic Acids Res* 34, W516-23.
- Mann, J.M., Chin, J., Piot, P. and Quinn, T. (1988) The international epidemiology of AIDS. *Sci Am* 259, 82-9.
- Marasco, W.A., Haseltine, W.A. and Chen, S.Y. (1993) Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody. *Proc Natl Acad Sci U S A* 90, 7889-93.
- Marchetti, A., Buttitta, F., Miyazaki, S., Gallahan, D., Smith, G.H. and Callahan, R. (1995) Int-6, a highly conserved, widely expressed gene, is mutated by mouse mammary tumor virus in mammary preneoplasia. *J Virol* 69, 1932-8.

- Mazumder, A., Engelman, A., Craigie, R., Fesen, M. and Pommier, Y. (1994) Intermolecular disintegration and intramolecular strand transfer activities of wild-type and mutant HIV-1 integrase. *Nucleic Acids Res* 22, 1037-43.
- McGraw-Hill. (2006) HIV replication. [online] Available <http://highered.mcgraw-hill.com/olc/dl/120088/micro41.swf>. (2011, January 29).
- Mighell, A.J., Markham, A.F. and Robinson, P.A. (1997) Alu sequences. *FEBS Lett* 417, 1-5.
- Miller, J., McLachlan, A.D. and Klug, A. (1985) Repetitive zinc-binding domains in the protein transcription factor IIIA from *Xenopus* oocytes. *EMBO J* 4, 1609-14.
- Muesing, M.A., Smith, D.H., Cabradilla, C.D., Benton, C.V., Lasky, L.A. and Capon, D.J. (1985) Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus. *Nature* 313, 450-8.
- Nair, R. and Rost, B. (2005) Mimicking cellular sorting improves prediction of subcellular localization. *J Mol Biol* 348, 85-100.
- Naldini, L., Blomer, U., Gage, F.H., Trono, D. and Verma, I.M. (1996a) Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. *Proc Natl Acad Sci U S A* 93, 11382-8.
- Naldini, L., Blomer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F.H., Verma, I.M. and Trono, D. (1996b) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. *Science* 272, 263-7.

- Neala, K. (1999) HIV as a lentiviral vector in gene therapy. [online] Available: <http://biology.kenyon.edu/slonec/gene-web/Lentiviral/index.htm> (2011, April 19).
- O'Doherty, U., Swiggard, W.J., Jeyakumar, D., McGain, D. and Malim, M.H. (2002) A sensitive, quantitative assay for human immunodeficiency virus type 1 integration. *J Virol* 76, 10942-50.
- Ofotokun, I. and Weitzmann, M.N. (2010) HIV-1 infection and antiretroviral therapies: risk factors for osteoporosis and bone fracture. *Curr Opin Endocrinol Diabetes Obes* 17, 523-9.
- Palella, F.J., Jr., Delaney, K.M., Moorman, A.C., Loveless, M.O., Fuhrer, J., Satten, G.A., Aschman, D.J. and Holmberg, S.D. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. *N Engl J Med* 338, 853-60.
- Pan, T. and Coleman, J.E. (1990) GAL4 transcription factor is not a "zinc finger" but forms a $Zn(II)_2Cys_6$ binuclear cluster. *Proc Natl Acad Sci U S A* 87, 2077-81.
- Papworth, M., Kolasinska, P. and Minczuk, M. (2006) Designer zinc-finger proteins and their applications. *Gene* 366, 27-38.
- Patel, S.D., Isalan, M., Gavory, G., Ladame, S., Choo, Y. and Balasubramanian, S. (2004) Inhibition of human telomerase activity by an engineered zinc finger protein that binds G-quadruplexes. *Biochemistry* 43, 13452-8.
- Pauza, C.D. (1990) Two bases are deleted from the termini of HIV-1 linear DNA during integrative recombination. *Virology* 179, 886-9.

- Pauza, C.D., Trivedi, P., McKechnie, T.S., Richman, D.D. and Graziano, F.M. (1994) 2-LTR circular viral DNA as a marker for human immunodeficiency virus type 1 infection in vivo. *Virology* 205, 470-8.
- Pavletich, N.P. and Pabo, C.O. (1991) Zinc finger-DNA recognition: crystal structure of a Zif268-DNA complex at 2.1 Å. *Science* 252, 809-17.
- Pollock, R., Giel, M., Linher, K. and Clackson, T. (2002) Regulation of endogenous gene expression with a small-molecule dimerizer. *Nat Biotechnol* 20, 729-33.
- Ramezani, A., Ma, X.Z., Nazari, R. and Joshi, S. (2002) Development and testing of retroviral vectors expressing multimeric hammerhead ribozymes targeted against all major clades of HIV-1. *Front Biosci* 7, a29-36.
- Ratner, L., Haseltine, W., Patarca, R., Livak, K.J., Starcich, B., Josephs, S.F., Doran, E.R., Rafalski, J.A., Whitehorn, E.A., Baumeister, K., et al., Muesing, M.A., Smith, D.H., Cabradilla, C.D., Benton, C.V., Lasky, L.A. and Capon, D.J. (1985) Complete nucleotide sequence of the AIDS virus, HTLV-III. Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus. *Nature* 313, 277-84.
- Rebar, E.J., Huang, Y., Hickey, R., Nath, A.K., Meoli, D., Nath, S., Chen, B., Xu, L., Liang, Y., Jamieson, A.C., Zhang, L., Spratt, S.K., Case, C.C., Wolffe, A. and Giordano, F.J. (2002) Induction of angiogenesis in a mouse model using engineered transcription factors. *Nat Med* 8, 1427-32.
- Rebar, E.J. and Pabo, C.O. (1994) Zinc finger phage: affinity selection of fingers with new DNA-binding specificities. *Science* 263, 671-3.

- Reisman, D. and Sugden, B. (1986) trans activation of an Epstein-Barr viral transcriptional enhancer by the Epstein-Barr viral nuclear antigen 1. *Mol Cell Biol* 6, 3838-46.
- Reynolds, L., Ullman, C., Moore, M., Isalan, M., West, M.J., Clapham, P., Klug, A. and Choo, Y. (2003) Repression of the HIV-1 5' LTR promoter and inhibition of HIV-1 replication by using engineered zinc-finger transcription factors. *Proc Natl Acad Sci U S A* 100, 1615-20.
- Sabin, C.A., Worm, S.W., Weber, R., Reiss, P., El-Sadr, W., Dabis, F., De Wit, S., Law, M., D'Arminio Monforte, A., Friis-Moller, N., Kirk, O., Pradier, C., Weller, I., Phillips, A.N. and Lundgren, J.D. (2008) Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. *Lancet* 371, 1417-26.
- Sakkhachornphop, S., Jiranusornkul, S., Kodchakorn, K., Nangola, S., Sirisanthana, T. and Tayapiwatana, C. (2009) Designed zinc finger protein interacting with the HIV-1 integrase recognition sequence at 2-LTR-circle junctions. *Protein Sci* 18, 2219-30.
- Schon, E.A. (2000) Mitochondrial genetics and disease. *Trends Biochem Sci* 25, 555-60.
- Schrager, L.K. and D'Souza, M.P. (1998) Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. *JAMA* 280, 67-71.

- Segal, D.J., Dreier, B., Beerli, R.R. and Barbas, C.F., 3rd. (1999) Toward controlling gene expression at will: selection and design of zinc finger domains recognizing each of the 5'-GNN-3' DNA target sequences. *Proc Natl Acad Sci U S A* 96, 2758-63.
- Segal, D.J., Goncalves, J., Eberhardy, S., Swan, C.H., Torbett, B.E., Li, X. and Barbas, C.F., 3rd. (2004) Attenuation of HIV-1 replication in primary human cells with a designed zinc finger transcription factor. *J Biol Chem* 279, 14509-19.
- Shaheen, F., Duan, L., Zhu, M., Bagasra, O. and Pomerantz, R.J. (1996) Targeting human immunodeficiency virus type 1 reverse transcriptase by intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle. *J Virol* 70, 3392-400.
- Sherman, P.A. and Fyfe, J.A. (1990) Human immunodeficiency virus integration protein expressed in *Escherichia coli* possesses selective DNA cleaving activity. *Proc Natl Acad Sci U S A* 87, 5119-23.
- Simons, K. and Gerl, M.J. (2010) Revitalizing membrane rafts: new tools and insights. *Nat Rev Mol Cell Biol* 11, 688-99.
- Skalka, A.M. (2011) Determination of the solution structure of full-length retroviral integrase monomers and dimers, using data from small angle X-ray scattering, crystallography, and biochemical studies analyses. [online] Available: <http://www.fccc.edu/research/pid/skalka/research.html>. (2011, April 19).
- Staunstrup, N.H., Moldt, B., Mates, L., Villesen, P., Jakobsen, M., Ivics, Z., Izsvak, Z. and Mikkelsen, J.G. (2009) Hybrid lentivirus-transposon vectors with a random integration profile in human cells. *Mol Ther* 17, 1205-14.

- Stege, J.T., Guan, X., Ho, T., Beachy, R.N. and Barbas, C.F., 3rd. (2002) Controlling gene expression in plants using synthetic zinc finger transcription factors. *Plant J* 32, 1077-86.
- Stevenson, M., Stanwick, T.L., Dempsey, M.P. and Lamonica, C.A. (1990) HIV-1 replication is controlled at the level of T cell activation and proviral integration. *EMBO J* 9, 1551-60.
- Strayer, D.S., Akkina, R., Bunnell, B.A., Dropulic, B., Planelles, V., Pomerantz, R.J., Rossi, J.J. and Zaia, J.A. (2005) Current status of gene therapy strategies to treat HIV/AIDS. *Mol Ther* 11, 823-42.
- Strayer, D.S., Branco, F., Landre, J., BouHamdan, M., Shaheen, F. and Pomerantz, R.J. (2002) Combination genetic therapy to inhibit HIV-1. *Mol Ther* 5, 33-41.
- Su, K., Wang, D., Ye, J., Kim, Y.C. and Chow, S.A. (2009) Site-specific integration of retroviral DNA in human cells using fusion proteins consisting of human immunodeficiency virus type 1 integrase and the designed polydactyl zinc-finger protein E2C. *Methods* 47, 269-76.
- Tamhane, M. and Akkina, R. (2008) Stable gene transfer of CCR5 and CXCR4 siRNAs by sleeping beauty transposon system to confer HIV-1 resistance. *AIDS Res Ther* 5, 16.
- Tan, W., Zhu, K., Segal, D.J., Barbas, C.F., 3rd and Chow, S.A. (2004) Fusion proteins consisting of human immunodeficiency virus type 1 integrase and the designed polydactyl zinc finger protein E2C direct integration of viral DNA into specific sites. *J Virol* 78, 1301-13.
- Temin, H.M. and Mizutani, S. (1970) RNA-dependent DNA polymerase in virions of Rous sarcoma virus. *Nature* 226, 1211-3.

- Tesio, M., Gammaitoni, L., Gunetti, M., Leuci, V., Pignochino, Y., Jordaney, N., Capellero, S., Cammarata, C., Caione, L., Migliaretti, G., Fagioli, F., Tabilio, A., Aglietta, M. and Piacibello, W. (2008) Sustained long-term engraftment and transgene expression of peripheral blood CD34+ cells transduced with third-generation lentiviral vectors. *Stem Cells* 26, 1620-7.
- Tewari, D., Notkins, A.L. and Zhou, P. (2003) Inhibition of HIV-1 replication in primary human T cells transduced with an intracellular anti-HIV-1 p17 antibody gene. *J Gene Med* 5, 182-9.
- Thiesen, H.J., Bellefroid, E., Revelant, O. and Martial, J.A. (1991) Conserved KRAB protein domain identified upstream from the zinc finger region of Kox 8. *Nucleic Acids Res* 19, 3996.
- Turner, B.G. and Summers, M.F. (1999) Structural biology of HIV. *J Mol Biol* 285, 1-32.
- UNAIDS/WHO. (2010) AIDS epidemic update. [online] Available: http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2010/20101123_globalreport_en.pdf (2011, September 1).
- van den Ent, F.M., Vink, C. and Plasterk, R.H. (1994) DNA substrate requirements for different activities of the human immunodeficiency virus type 1 integrase protein. *J Virol* 68, 7825-32.
- Van Maele, B. and Debyser, Z. (2005) HIV-1 integration: an interplay between HIV-1 integrase, cellular and viral proteins. *AIDS Rev* 7, 26-43.

- Vandegraaff, N., Kumar, R., Burrell, C.J. and Li, P. (2001) Kinetics of human immunodeficiency virus type 1 (HIV)-DNA integration in acutely infected cells as determined using a novel assay for detection of integrated HIV DNA. *J Virol* 75, 11253-60.
- Vercruysse, T., Pardon, E., Vanstreels, E., Steyaert, J. and Daelemans, D. (2010) An intrabody based on a llama single-domain antibody targeting the N-terminal alpha-helical multimerization domain of HIV-1 rev prevents viral production. *J Biol Chem* 285, 21768-80.
- Vink, C. and Plasterk, R.H. (1993) The human immunodeficiency virus integrase protein. *Trends Genet* 9, 433-8.
- Vink, C., van Gent, D.C., Elgersma, Y. and Plasterk, R.H. (1991) Human immunodeficiency virus integrase protein requires a subterminal position of its viral DNA recognition sequence for efficient cleavage. *J Virol* 65, 4636-44.
- Walther, W. and Stein, U. (2000) Viral vectors for gene transfer: a review of their use in the treatment of human diseases. *Drugs* 60, 249-71.
- Weissenhorn, W., Dessen, A., Harrison, S.C., Skehel, J.J. and Wiley, D.C. (1997) Atomic structure of the ectodomain from HIV-1 gp41. *Nature* 387, 426-30.
- Whitcomb, J.M., Kumar, R. and Hughes, S.H. (1990) Sequence of the circle junction of human immunodeficiency virus type 1: implications for reverse transcription and integration. *J Virol* 64, 4903-6.
- Wilkins, M.R., Gasteiger, E., Bairoch, A., Sanchez, J.C., Williams, K.L., Appel, R.D. and Hochstrasser, D.F. (1999) Protein identification and analysis tools in the ExPASy server. *Methods Mol Biol* 112, 531-52.

- Wu, H., Yang, W.P. and Barbas, C.F., 3rd. (1995) Building zinc fingers by selection: toward a therapeutic application. *Proc Natl Acad Sci U S A* 92, 344-8.
- Wu, Y. and Marsh, J.W. (2001) Selective transcription and modulation of resting T cell activity by preintegrated HIV DNA. *Science* 293, 1503-6.
- Yaghmai, R. and Cutting, G.R. (2002) Optimized regulation of gene expression using artificial transcription factors. *Mol Ther* 5, 685-94.
- Yates, J.L., Warren, N. and Sugden, B. (1985) Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. *Nature* 313, 812-5.
- Yoder, K.E. and Bushman, F.D. (2000) Repair of gaps in retroviral DNA integration intermediates. *J Virol* 74, 11191-200.
- Yoshinaga, T. and Fujiwara, T. (1995) Different roles of bases within the integration signal sequence of human immunodeficiency virus type 1 in vitro. *J Virol* 69, 3233-6.
- Zahm, J.A., Bera, S., Pandey, K.K., Vora, A., Stillmock, K., Hazuda, D. and Grandgenett, D.P. (2008) Mechanisms of human immunodeficiency virus type 1 concerted integration related to strand transfer inhibition and drug resistance. *Antimicrob Agents Chemother* 52, 3358-68.
- Zhou, Y., Zhang, H., Siliciano, J.D. and Siliciano, R.F. (2005) Kinetics of human immunodeficiency virus type 1 decay following entry into resting CD4⁺ T cells. *J Virol* 79, 2199-210.
- Zimmerman, K.A., Fischer, K.P., Joyce, M.A. and Tyrrell, D.L. (2008) Zinc finger proteins designed to specifically target duck hepatitis B virus covalently closed circular DNA inhibit viral transcription in tissue culture. *J Virol* 82, 8013-21.

Zufferey, R., Dull, T., Mandel, R.J., Bukovsky, A., Quiroz, D., Naldini, L. and Trono, D. (1998) Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. *J Virol* 72, 9873-80.

Zufferey, R., Nagy, D., Mandel, R.J., Naldini, L. and Trono, D. (1997) Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. *Nat Biotechnol* 15, 871-5.



APPENDICES

APPENDIX A

LIST OF THE CHEMICALS AND INSTRUMENTS

1. Chemicals

All chemicals used as in this study were analytical grade reagents.

Chemical name	Source
4', 6-diamidino-2-phenylindole (DAPI)	Molecular Probes, Eugene, OR, USA
Acrylamide	Biorad, Hercules, CA, USA
Agarose (electrophoresis grade)	Sigma-Aldrich. St.Louis, MO, USA
Amersham Hybond TM -ECL	GE healthcare Bio-Sciences Co. Piscataway, NJ, USA
Ampiillin	Sigma-Aldrich. St.Louis, MO, USA
BCA Protein Assay	Thermo Fisher Scientific Inc., Rockford, IL, USA
BIACORE 2000 TM biosensor	Biacore AB, Uppsala, Sweden
Bis-acrylamide	Biorad, Hercules, CA, USA
Bovine Serum Albumin (BSA)	Sigma-Aldrich. St.Louis, MO, USA
<i>B-PER II</i> Bacterial Protein Extraction Reagent	Pierce, Rockford, IL, USA
Bromphenol blue	Sigma-Aldrich. St.Louis, MO, USA

Chemical name	Source
COBAS [®] AMPLICOR HIV-1 Monitor Test, v1.5	Roche Molecular Systems, Inc., Branchburg, NJ, USA
DTT	AMRESCO, Salon, OH, USA
Dulbecco's Modified Eagle's medium (DMEM)	Gibco, Grand Island, NY, USA
ECL system	GE Healthcare, Buckinghamshire, UK
EDTA	Sigma-Aldrich. St.Louis, MO, USA
EMSA kit [E33075]	Invitrogen, Paisley, UK
Ethanol	Merck, Darmstadt, Germany
Ethidium bromide	Sigma-Aldrich. St.Louis, MO, USA
Fetal bovine serum (FBS)	HyClone, Cramlington, UK
GENETIC SYSTEM [™] HIV-1 Ag EIA kit	Bio-Rad Laboratories, Redmond, WA, USA
Glacial acetic acid	BDH Laboratory Supplies, UK
Glycerol	Sigma-Aldrich. St.Louis, MO, USA
High Pure PCR Template Preparation Kit	Roach, Mannheim, Germany
His-bind column chromatography	Novagen, San Diego, CA, USA

Chemical name	Source
Hybond-P polyvinylidene fluoride (PVDF) membrane	Amersham Bioscience, Piscataway, NJ, USA
Imidazole	Sigma-Aldrich. St.Louis, MO, USA
isopropyl β -D-thiogalactopyranoside (IPTG) , dioxan-free	Fermentas, Burlington, ON, Canada
Kanamycin	Sigma-Aldrich. St.Louis, MO, USA
LB Broth Agar	Bio Basic inc., Ontario, Canada
L-glutamine	Gibco, Grand Island, NY, USA
Lipofectamine	Invitrogen, Carlsbad, CA, USA
Methanol	Merck, Darmstadt, Germany
Micro-BCA protein assay	Pierce, Rockford, IL, USA
Millipore Millex-HA filter unit, 0.45 μ m	Millipore, Cork, Ireland
NaCl	Sigma-Aldrich. St.Louis, MO, USA
NaOH	Sigma-Aldrich. St.Louis, MO, USA
Nucleofector™ transfection reagent V	Lonza, Basel, Switzerland
Paraformaldehyde	Sigma-Aldrich. St.Louis, MO, USA
Plus Reagent	Invitrogen, Carlsbad, CA, USA
polybrene	Sigma-Aldrich. St.Louis, MO, USA
PureLink Quick Plasmid Miniprep Kit	Invitrogen, Carlsbad, CA, USA
QIAGEN Miniprep Kit	Qiagen, Hilden, Germany

Chemical name	Source
Sensor chip SA	Biācore AB, Uppsala, Sweden
TEMED	Biorad, Hercules, CA, USA
Tetracyclin	Sigma-Aldrich. St.Louis, MO, USA
Triton X-100	Sigma-Aldrich. St.Louis, MO, USA
Trypan Blue 0.2%	Sigma-Aldrich. St.Louis, MO, USA
Tryptone water	Merck, Darmstadt, Germany
Tween 20	Fluka, Buchs, Switzerland
Yeast extract	Bio Basic inc., Ontario, Canada

2. Instruments

Instruments	Source
37 °C CO ₂ incubator EG 115 IR	Jouan GmbH, Unterhaching, Germany
37 °C incubator	JP Selecta, Barcelona, Spain
BioRad Chemidoc XRS Gel Documentation System	BioRad, Hercules, CA, USA
BECKMAN L-60 ultracentrifuge	Beckman Coulter, Fullerton, CA, USA
Carl Zeiss MicroImaging LSM 700 confocal laser scanning microscope	Carl Zeiss MicroImaging GmbH, Germany
Electrophoretic power supply 3000Xi	BioRad, Hercules, CA, USA
Flow cytometer (BD FACSCalibur™)	BD Biosciences, San Diego, CA, USA
Fluorescence microscopy, OLYMPUS AX70	Olympus, Tokyo, Japan
Shaking incubator (JSSI-100C)	JS Research Inc., Gongju-city, Korea
Inverted fluorescence microscope	Nikon eclipse TE2000-S, Japan
Inverted microscope	Olympus, Japan
Laminar Flow biological safety cabinet	NUAIRE, Plymouth, MN, USA
Microcentrifuge	Eppendorf AG, Hamburg, Germany
Microplate	NUNC, Roskilde, Denmark
MiniVE vertical electrophoresis system	Amersham Pharmacia Biotech, Buckinghamshire, UK

Instruments	Source
MJ Mini™ Thermal Cycler and MiniOpticon™ Real-Time PCR System	BioRad, Hercules, CA, USA
MRX-150 Refrigerated microcentrifuge	Tomy Tech USA Inc., CA, USA
MTP-120 ELISA plate reader	Corona Electric, Japan
NanoDrop 2000	ThermoScientific, Rockford, IL, USA
Nucleofector™	Amaxa, Koeln, Germany
Typhoon Trio phosphorImager	GE Healthcare Biosciences, Piscataway, NJ
Ultrasonic Processor UP100H	Hielscher, Teltow, Germany
UV spectrophotometer	Shimadzu Scientific Instruments Inc, Kyoto, Japan
UV-2450/2550 spectrophotometer	Shimadzu, Columbia, MD, USA
Vortex-Genie K-550-GE	Scientific Industries Inc, Bohemia, NY, USA

APPENDIX B

LIST OF CELL LINES AND MICROORGANISMS

1. Cell lines

Name	Type of cell lines
HeLa	Cervical carcinoma cell
Sup T1	Human T cell lymphocytic cell line
293T	Human embryonic kidney cell

2. Microorganisms

2.1 *Escherichi coli* XL-1 Blue MRF'

Genotype: $\Delta(mcrA)183 \Delta(mcrCB-hsdSMR-mrr)173 \text{ endA1 } supE44 \text{ thi-1 } recA1$
 $gyrA96 \text{ relA1 } lac [F' \text{ proAB } lacI^qZ\Delta M15 \text{ Tn10 } (Tet^r)]$

2.2 *Escherichi coli* BL21 (DE3)

Genotype: $F^- \text{ ompT } gal \text{ dcm } lon \text{ hsdS}_B (r_B^- \text{ m}_B^-) \lambda(\text{DE3 } [lacI \text{ lacUV5-T7 gene 1 } ind1$
 $sam7 \text{ nin5}])$

APPENDIX C

LIST OF ANTIBODIES AND CONJUGATED ANTIBODIES

Antibodies name	Source
Anti-CD4 mAb	Kindly provided by Prof. Dr. Watchara Kasinrerak
Anti-His tag antibody	GenScript, Piscataway, NJ, USA
Horseradish peroxidase (HRP) - labeled goat anti-mouse immunoglobulins	Sigma, St Louis, MO, USA
Polyclonal Rabbit Anti-mouse Immunoglobulins/RPE, Rabbit F(ab') ₂	DAKO, Denmark

APPENDIX D

LIST OF ENZYMES

Enzymes	Sources
Accuprime™ Pfx DNA polymerase	Invitrogen, San Diego, CA
DyNAmo™ probe qPCR	Finnzymes, Espoo, Finland
<i>Nhe</i> I	NEB, Pickering, Ontario, USA
<i>Not</i> I	NEB, Pickering, Ontario, USA
5 PRIME MasterMix (2.5X)	5 Prime, Gaithersburg, MD, USA
<i>Sma</i> I	Fermentas, Glen. Burnie, MD, USA
T4 DNA ligase enzyme	NEB, Pickering, Ontario, USA
<i>Xcm</i> I	NEB, Pickering, Ontario, USA

APPENDIX E

REAGENT PREPARATIONS

1. Reagents for gel electrophoresis

1.1 10× Tris-acetate/EDTA electrophoresis buffer (TAE)

Tris-base	48.40	gm
Glacial acetic acid	11.42	ml
0.5 M EDTA, pH 8.0	20	ml

Dissolved all ingredients in deionized distilled water and filled up to 1,000 ml.

Sterilized by autoclave and kept at room temperature.

1.2 1 or 2 % Agarose gel

Agarose	1 or 2	gm
1× TAE	100	ml

Melted by microwave oven until the agarose was completely dissolved.

1.3 Ethidium bromide working solution (10 mg/ml)

Ethidium bromide	1.0	gm
Distilled water	100	ml

Dissolved and kept in dark bottle at 4 °C.

1.4 6X gel loading buffer

Bromphenol blue	0.25	%
Glycerol	30	%

Mixed thoroughly and stored at -20 °C.

2. Reagents for SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting**2.1 1.5 M Tris-HCl, pH 8.8**

Tris-base	18.15	gm
-----------	-------	----

Dissolved in 75 ml deionized distilled water.

Adjusted pH to 8.8 with concentrated HCL.

Adjusted the volume to 100 ml with deionized distilled water
stored at 4 °C.

2.2 0.5 M Tris-HCl, pH 6.8

Tris-base	6.0	gm
-----------	-----	----

Dissolved in 75 ml deionized distilled water.

Adjusted pH to 6.8 with concentrated HCl.

Adjusted the volume to 100 ml with deionized distilled water
and stored at 4 °C.

2.3 Running buffer

Tris-base	1.51	gm
Glycine	7.20	gm
Sodium dodesyl sulfate	0.5	gm

Dissolved in 500 ml deionized distilled water and kept at 4 °C.

2.4 Blotting buffer

Tris-base	3.03	gm
Glycine	14.41	gm
SDS	0.5	gm

Added deionized distilled water to 700 ml and mixed well.

Added 200 ml of methanol

Adjusted the volume to 1,000 ml with deionized distilled water and kept at 4 °C.

2.5 Copolymerization of 4% stacking gel (5 ml)

Stock acrylamide 30%	0.83	ml
0.5 M Tris-HCl pH 6.8	0.63	ml
10% SDS	0.05	ml
DW	3.40	ml
10% Ammonium persulfate	0.05	ml
TEMED	0.01	ml

2.6 Copolymerization of 12% stacking gel (10 ml)

Stock acrylamide 30%	4.00	ml
Gel buffer pH 8.8	2.50	ml
10% SDS	0.10	ml
DW	3.30	ml
10% Ammonium persulfate	0.10	ml
TEMED	0.01	ml

3. Reagents for Electrophoretic mobility shift assay (EMSA)**3.1 Running buffer (10X TB buffer, pH 8.2)**

Tris-base	108	gm
Boric acid	55	gm

Dissolved in 750 ml deionized distilled water.

Adjusted pH to 8.2 with concentrated HCL.

Adjusted the volume to 1000 ml with deionized distilled water stored at 4 °C.

3.2 Copolymerization of 5% Native gel (60 ml)

Stock 29:1 acrylamide/Bis (w/w)	10.0	ml
10 X TBE buffer	3.0	ml
DW	47.0	ml
10% Ammonium persulfate	0.25	ml
TEMED	0.034	ml

4. Reagents for surface plasmon resonance (SPR)

4.1 Washing solution (50 mM NaOH/ 1M NaCl)

5 M NaOH	1.0	ml
5 M NaCl	20	ml

Adjusted the volume to 100 ml with deionized distilled water

Filtered with 0.2 μ m Millipore filter and stored at 4 °C.

4.2 Zinc buffer (200 ml)

1.5 M Tris-HCl, pH 7.5	1.33	ml
0.5 M KCl	36.0	ml
1 M MgCl ₂	0.2	ml
100 mM ZnSO ₄	180	μ l
100 mM dithiothreitol (DTT)	10	ml
100 mM phenylmethylsulfonylfluoride (PMSF)]	1	ml

Adjusted the volume to 200 ml with distilled water

Filtered with 0.2 μ m Millipore filter stored at 4 °C.

3. Medium for bacterial culture

3.1 50% glucose

D-glucose	5	gm
-----------	---	----

Added distilled water to 10 ml and boiled in boiling water.

Filtered through 0.2 μ m Millipore filter and stored at 4 °C.

3.2 LB broth

Yeast extract	5.0 gm
Tryptone	10.0 gm
NaCl	10.0 gm

Dissolved all ingredients in 1,000 ml distilled water

Sterilized by autoclave, and kept at 4 °C.

3.3 LB agar

LB agar	15 gm
---------	-------

Dissolved all ingredients in 1,000 ml distilled water.

Sterilized by autoclave, poured on Petri dish (plate) and stored at 4 °C.

3.4 Terrific broth

Tryptone	12 gm
Yeast extract	24 gm
Glycerol	4 ml

Adjusted to in 900 ml with distilled water.

Sterilized by autoclave and allowed to cool to room temperature

Adjust volume to 1,000 ml with 100 ml of a filter sterilized solution of

0.17M KH_2PO_4 and 0.72M K_2HPO_4

4. Reagents for fluorescence microscopy and flow cytometry analysis

4.1 4% Paraformaldehyde in PBS

Paraformaldehyde	4	gm
------------------	---	----

PBS pH 7.2	100	ml
------------	-----	----

Heat at 56°C until dissolved

Filtered with 0.2 µm Millipore filter, stored at 4°C.

4.2 1% BSA-PBS- NaN_3

BSA	1	gm
-----	---	----

NaN_3	0.09	gm
----------------	------	----

Dissolved in PBS 100 ml

4.3 0.2% Triton X-100

Triton X-100	0.2	ml
--------------	-----	----

Dissolved in PBS 100 ml

5. Reagents for cell culture

5.1 RPMI 1640 medium

RPMI powder	1	pack
-------------	---	------

NaHCO_3	2	gm
------------------	---	----

ddH ₂ O	800	ml
--------------------	-----	----

Penicillin (10,000 units/ml)/Streptomycin	1	ml
---	---	----

(10,000 µg/ml)

Stirred until dissolved and adjusted pH with acetic acid.

Dissolved in ddH₂O and adjust volume to 1,000 ml.

Filtered through 0.2 µm Millipore membrane filter.

Mixed and stored at 4 °C.

5.2 Complete RPMI culture medium

RPMI 1640 medium	90	ml
------------------	----	----

Fetal bovine serum (FBS)	10	ml
--------------------------	----	----

Checked sterility before used.

5.3 Freezing medium (10%DMSO in 90%FCS)

Fetal bovine serum (FBS)	9	ml
--------------------------	---	----

DMSO	1	ml
------	---	----

Fresh preparation before use.

5.4 Trypan blue (0.2%)

Trypan blue powder	0.2	gm
--------------------	-----	----

PBS pH 7.2	100	ml
------------	-----	----

Filtered by Whatman filter paper No. 1 and

Stored at room temperature.

APPENDIX F

PRESENTATIONS AND PUBLICATIONS

List of presentation

1. Designed Zinc Finger Protein Interacting with the HIV-1 Integrase Recognition Sequence at 2-LTR-Circle Junctions. 3rd Annual meeting of the Faculty of Associated Medical Sciences Chiang Mai, Thailand. 11 June 2009 (Excellent oral presentation award).
2. Designed Zinc Finger Protein Interacting with the HIV-1 Integrase Recognition Sequence at 2-LTR-Circle Junctions. RGJ seminar series LXXIV “From basic biomedical research to sustainable development”. Chiang Mai, Thailand. 16 September 2010 (Poster presentation).
3. Designed Zinc Finger Protein Interacting with the HIV-1 Integrase Recognition Sequence at 2-LTR-Circle Junctions. The Fogarty International Clinical Research Scholars and Fellow and Doris Duke International Fellows Alumni Symposium. Bolger Center, Potomac, MD, USA. September 23 - 26, 2010 (Poster presentation)
4. The Innovative Strategy for HIV-1 Gene Therapy by Zinc Finger Protein. The 28th Annual Meeting of Allergy, Asthma, and Immunology Association of Thailand. Plaza Athenee, Bangkok, April 3-5, 2012 (Winner of MSD Investigator Awards)

List of publications

1. **Sakkhachornphop, S.**, Jiranusornkul, S., Kodchakorn, K., Nangola, S., Sirisanthana, T. and Tayapiwatana, C. (2009) Designed zinc finger protein interacting with the HIV-1 integrase recognition sequence at 2-LTR-circle junctions. *Protein Sci* 18, 2219-30.

Impact Factor 2.937

2. **Sakkhachornphop, S.**, Barbas III, C., Keawvichit, R., Wongworapat, K. and Tayapiwatana, C. (2012) Zinc Finger Protein Designed to Target 2-LTR Junctions Interferes with HIV Integration. *Human Gene Therapy*, (accepted)

Impact Factor 4.829

CURRICULUM VITAE

Name	Mr Supachai Sakkhachornphop
Date of birth	July 12 th , 1975
Education	
1993-1996	Bachelor of Science (Medical Technology), Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand
2003-2006	Master of Science (Health Sciences), The Graduate School, Chiang Mai University, Chiang Mai, Thailand
Working experiences	
1997 – 1999	Medical Technologist, Central Chiang Mai Memorial Hospital, Chiang Mai, Thailand
1999 – present	Medical Technologist and Research Assistance, The Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand

Practical training and research fellowships

2004	Training in HIV subtyping at U.S. Military HIV Research Program (USMHRP), Henry M. Jackson Foundation, Rockville, MD, USA
2004-2005	Research Fellow of the Fogarty/Ellison Fellowship Program in global health and clinical research.
2007-2009	Research Fellow of the Fogarty International Clinical Research.
2009	Training in zinc finger protein and lentiviral gene transfer at the Scripps Research Institute, San Diego, CA, USA.

List of publications and presentations

1. **Sakkhachornphop S**, Pichyangkul S, and Hirunpetcharat C. 2000. Production and purification of the 19- kDa carboxyl-terminal fragment of *Plasmodium yoelii* merozoite surface protein-1 (MSP1₁₉) as a flag fusion protein expressed in *Saccharomyces cerevisiae*. *Bull Chiang Mai Assoc Med Sci* ;33 : 161-71.
2. Hirunpetcharat C, **Sakkhachornphop S**, Pichyangkul S, Krieg AM, and Good MF. Protective immunity induced in mice by parenteral immunization with yeast-expressed 19 kDa carboxyl terminal fragment of *Plasmodium yoelii* merozoite surface protein-1 (MSP1₁₉) using montanide 51, montanide 720 and CpG oligodeoxynucleotides as adjuvants. Presented at the 18th Annual Health Sciences Meeting. June 8, 2000. Reserch Institute for Health Sciences. Chiang Mai University.
3. Chearwae W, **Sakkhachornphop S**, Chumpookhod A, Chumpookhod S, Palanan P, Tejafong K, Kitisri J, and Chanbancherd P. Application of dried blood spots in molecular epidemiological study of HIV-1. Presented at the 19th Annual Health Sciences Meeting. August 24, 2001. Research Institute for Health Sciences. Chiang Mai University.
4. Hirunpetcharat C, Wipasa J, **Sakkhachornphop S**, Nitkumhan T, Zheng YZ, Pichyangkul S, Krieg AM, Walsh DS, Heppner DG, and Good MF. CpG oligonucleotide enhances immunity blood-stage malaria infection in mice parenterally immunized with a yeast-expressed 19 kDa carboxyl-terminal fragment of *Plasmodium yoelii* merozoite surface protein-1 (MSP1₁₉) formulated in oil-based Montanides. *Vaccine* 2003; 21: 2923-32.

5. Tovanabutra S, Beyrer C, **Sakkhachornphop S**, *et al.* The Changing Molecular Epidemiology of HIV-1 among Northern Thai Drug Users, 1999 to 2002. *AIDS Res Hum Retroviruses* 2004; 20 :Number 5 : Issue date May 2004
6. **Sakkhachornphop S**, Tovanabutra S, Kijak G, *et al.* Development and Application of the Multi-region Subtype Specific PCR (MSSP) Assay for HIV-1 Subtypes B, C, CRF01_AE, Their Recombinant Forms, and Dual Infections. Oral presentation at the 13th HIV Dynamics and Evolution. April 5-8, 2006. Marine Biology Labs. Woods Hole. MA. USA.
7. Quan V.M., Celentano D.D., Rungruengthanakit K, Pasawad W, Vongchak T, **Sakkhachornphop S**, *et al.* Decline in CD4+ T lymphocyte count among substance abuse patients within one year after HIV-1 infection. Poster presentation at the XVI International AIDS Conference. August 13-18, 2006. Toronto. Canada.
8. Tovanabutra S, Kijak G, Beyrer C, Gammon-Richardson C, **Sakkhachornphop S**, *et al.* The link between multiple HIV-1 exposure and genetic complexity of strains is reinforced by identification of a second circulating recombinant form among injecting drug users in northern Thailand. Poster presentation at the XVI International AIDS Conference. August 13-18, 2006. Toronto. Canada.
9. **Sakkhachornphop S**, Tovanabutra S, Kijak G, *et al.* Screening for Circulating Recombinant Forms of HIV-1 among Northern Thai Drug Users with a Multi-region Subtype Specific PCR (MSSP) Assay. Poster presentation at the 5th Joint Seminar on Biomedical Sciences. October 26-27, 2006. Kunming. China.

10. Tovanabutra S, Kijak G, Beyrer C, Gammon-Richardson C, **Sakkhachornphop S**, *et al.* Identification of CRF34_01B, a second circulating recombinant form unrelated to and more complex than CRF15_01B, among injecting drug users in northern Thailand. *AIDS Res Hum Retroviruses*. 2007 Jun; 23(6):829-33.
11. **Sakkhachornphop S**, Tovanabutra S, Kijak G, *et al.* Development and Application of the Multi-region Subtype Specific PCR (MSSP) Assay for HIV-1 Subtypes B, C, CRF01_AE, Their Recombinant Forms, and Dual Infections. (in preparation)
12. Utaipat U, Ketkarn J, **Sakkhachornphop S**, *et al.* Duration of infection and low CD4:CD8 ratio correlate with CXCR4 utilization among HIV-1 subtype CRF01-AE. Poster presentation at the 4th IAS Conference on HIV Pathogenesis, Treatment, and Prevention incorporating the 19th ASHM Conference. July 22-25, 2007. Sydney. Australia.
13. **Sakkhachornphop S**, Tovanabutra S, Kijak G, *et al.* Development and Application of the Multi-region Subtype Specific PCR (MSSP) Assay for HIV-1 Subtypes B, C, CRF01_AE, Their Recombinant Forms, and Dual Infections. Oral presentation at the Fogarty International Clinical Research Scholars Program's Scientific Session. March 9 - 11, 2008. Marriott Bethesda and National Institutes of Health, Bethesda, MD, USA.
14. **Sakkhachornphop S**, Jiranusornkul, Kodchakorn K, Nangola S, Sirisanthana T, and Tayapiwatana C. Designed Zinc Finger Protein Interacting with the HIV-1 Integrase Recognition Sequence at 2-LTR-Circle Junctions. *Protein Sci*. 2009 Nov; 18(11):2219-30.

15. **Sakkhachornphop S**, Jiranusornkul, Kodchakorn K, Nangola S, Sirisanthana T, and Tayapiwatana C. Designed Zinc Finger Protein Interacting with the HIV-1 Integrase Recognition Sequence at 2-LTR-Circle Junctions. Poster presentation at the Fogarty International Clinical Research Scholars and Fellow and Doris Duke International Fellows Alumni Symposium. September 23 - 26, 2010. Bolger Center, Potomac, MD, USA.
16. Wipasa J, Okell L, **Sakkhachornphop S**, Suphavitai C, Chawansuntati K, Liewsaree W, Hafalla JC, Riley EM. Short-lived IFN- γ effector responses, but long-lived IL-10 memory responses, to malaria in an area of low malaria endemicity. PLoS Pathog. 2011 Feb 10; 7(2):e1001281.

Designed zinc finger protein interacting with the HIV-1 integrase recognition sequence at 2-LTR-circle junctions

Supachai Sakkhachornphop,^{1,2} Supat Jiranusornkul,³ Kanchanok Kodchakorn,⁴ Sawitree Nangola,¹ Thira Sirisanthana,² and Chatchai Tayapiwatana^{1,5*}

¹Division of Clinical Immunology, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50200, Thailand

²Research Institute for Health Sciences, Chiang Mai University, Chiang Mai 50200, Thailand

³Department of Pharmaceutical Sciences, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand

⁴Thailand Excellence Center for Tissue Engineering, Department of Biochemistry, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand

⁵Biomedical Technology Research Unit, National Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency at the Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50200, Thailand

Received 27 June 2009; Accepted 13 August 2009

DOI: 10.1002/pro.233

Published online 21 August 2009 proteinscience.org

Abstract: Integration of HIV-1 cDNA into the host genome is a crucial step for viral propagation. Two nucleotides, cytosine and adenine (CA), conserved at the 3' end of the viral cDNA genome, are cleaved by the viral integrase (IN) enzyme. As IN plays a crucial role in the early stages of the HIV-1 life cycle, substrate blockage of IN is an attractive strategy for therapeutic interference. In this study, we used the 2-LTR-circle junctions of HIV-1 DNA as a model to design zinc finger protein (ZFP) targeting at the end terminal portion of HIV-1 LTR. A six-contiguous ZFP, namely 2LTRZFP was designed using zinc finger tools. The designed motif was expressed and purified from *E. coli* to determine its binding properties. Surface plasmon resonance (SPR) was used to determine the binding affinity of 2LTRZFP to its target DNA. The level of dissociation constant (K_d) was 12.0 nM. The competitive SPR confirmed that 2LTRZFP specifically interacted with its target DNA. The qualitative binding activity was subsequently determined by EMSA and demonstrated the aforementioned correlation. In addition, molecular modeling and binding energy analyses were carried out to provide structural insight into the binding of 2LTRZFP to the specific and nonspecific DNA target. It is suggested that hydrogen-bonding interactions play a key role in the DNA recognition mechanisms of the designed ZFP. Our study suggested an alternative HIV therapeutic strategy using ZFP interference of the HIV integration process.

Keywords: HIV-1; AIDS; zinc finger protein; 2-LTR-circle junctions; molecular modeling

Abbreviations: AIDS, acquired immune deficiency syndrome; EMSA, electrophoretic mobility shift assay; GFP, green fluorescent protein; HIV-1, human immunodeficiency virus type 1; IN, integrase; LTR, long terminal repeat; MM/GBSA, molecular mechanics/generalized Born surface area; SPR, surface plasmon resonance; ZFP, zinc finger protein.

Grant sponsor: Royal Golden Jubilee Ph.D Program; Grant number: PHD/0112/2550; Grant sponsors: The Fogarty AIDS International for Research and Training Program, Johns Hopkins University, and the National Center for Genetic Engineering and Biotechnology (BIOTEC) of the National Science and Technology Development Agency, Thailand.

*Correspondence to: Chatchai Tayapiwatana, Division of Clinical Immunology, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50200, Thailand. E-mail: asimi002@chiangmai.ac.th

Introduction

Human immunodeficiency virus type 1 (HIV-1) is the etiologic agent of acquired immune deficiency syndrome (AIDS). It is one of the greatest health problems facing the world today.¹ According to UNAIDS and WHO, global estimates of the number of people living with HIV/AIDS as of the end of 2007 were 33 million adults and children.² HIV is a member of the family Retroviridae and subfamily lentivirinae. Soon after viral infection, the viral reverse transcriptase synthesizes a double-stranded DNA (ds-DNA). The subsequent insertion of viral genome into the host genome by integrase (IN) is a vital step in the HIV life cycle.^{3–5} Three forms of unintegrated viral DNA have been identified: a linear form which is flanked by long terminal repeat (LTR) copies at each terminus, and two circular molecules containing either one or two LTRs. The linear form is thought to be the substrate for integration.^{6–12} Integrase is involved in removing 2 bp from the 3' ends of viral DNA, the so-called 3' processing. The second reaction catalyzed by IN, i.e., strand transfer, inserts both 3' ends of HIV-1 DNA into the host genome.^{13,14}

Current antiretroviral drugs therapy for AIDS involves the use of a multidrug cocktail referred to as highly active antiretroviral therapy (HAART).¹⁵ IN inhibitors belong to a novel class of drugs that function by inhibiting integration of proviral DNA into the host cell genome. IN inhibitors can be divided into two groups: 3' processing and selective strand transfer inhibitors. These drugs are currently undergoing clinical trials.^{16,17} However, several questions concerning the interaction of IN with its inhibitors remain unclear, and resistant strains have been found.^{18–20} Therefore, a new approach targeting HIV-1 DNA at the level of the end terminal sequence of LTR by gene therapy may be a useful approach for inhibiting viral replication.

Our strategy herein is based on the specific DNA recognition by Cys₂His₂ zinc finger protein (ZFP). The Cys₂His₂ ZFP is the most common DNA-binding domain in the human and metazoan genome and plays a key role as a class of transcription factors. Its structure consists of a simple $\beta\beta\alpha$ fold of 30 amino acids in length, which is stabilized by hydrophobic interactions and chelation of a single zinc ion between two histidine residues and two cysteine residues.^{21,22} Within the residue at the N-terminus of the α -helix, the positions –1, 3, and 6 typically bind to three contiguous base pairs in a major groove of the target DNA.^{23,24} Therefore, several artificial ZFPs have been designed to target DNA sequences with high specificity and affinity.^{25–29}

The ZF Tools server³⁰ implements an effective algorithm to generate ZFPs for *in silico* or *in vivo* applications. The program facilitates web-based design of ZFPs that specifically recognize DNA sequence motifs. In this study, we used the 2-LTR-circle junction




Figure 1. Schematic representation of the circle junction region of HIV-1.⁴⁵ Predicted organization of U3, R, and U5 in 2-LTR-circle junctions shown above, whereas sequence in box was selected for designing the ZFP.

tions of HIV-1 DNA as a model to design a ZFP targeted at the end terminal part of HIV-1 LTR, which is a region for 3' processing by IN of HIV-1. We designed a six-contiguous ZFP. Binding affinity was carried out by surface plasmon resonance (SPR) and an electrophoretic mobility shift assay (EMSA). Molecular modeling was also used to gain structural insight into the DNA recognition patterns of the designed ZFP, in the cases of being bound to either a specific or a nonspecific DNA sequence. Relative binding energies of the specific and nonspecific complexes were also calculated.

Results

Procurement of the target sequence and designing the 2LTRZFP

To target the HIV-1 DNA sequence of 2-LTR-circle junctions, the DNA sequence was submitted to the zinc finger tools using "Search DNA Sequence for Contiguous Target Sites" mode. Eight candidate DNA sequences were obtained and the binding prediction scores of these sequences were selected for designing the ZFP. The sequence that had the highest score was 5' CTAGCAGTACTGGATGGG 3' (Fig. 1).

The design tool generated the full-length amino acid sequence of 2LTRZFP. This protein was composed of 176 amino acids [Fig. 2(A)] for a six zinc finger motif. Each finger was linked with the canonical TGEKP linker.

The amino acid sequence of 2LTRZFP was reverse-translated into a nucleotide sequence, and all codons in this sequence were optimized [Fig. 2(B)]. The full-length optimized sequence was sent for full-gene synthesis by Blue Heron Biotechnology. Predicted properties of the resulting proteins were computed using ExPaSy proteomics tools. The resulting theoretical pI/M_w was 9.46/20.1 kDa. Prediction of the protein subcellular localization using the LOctree program indicated that 2LTRZFP is a nuclear protein and is found in the nucleus.

Construction of pTriEx-4-2LTRZFP-GFP

The restriction endonucleases XcmI and SmaI in the plasmid vector pTriEx-4-GFP was used as a cloning sites for the 2LTRZFP gene fragment to construct the pTriEx-4-2LTRZFP-GFP containing His6 at N-




Figure 2. (A) Full-length amino acid sequence of 2LTRZFP. The amino acids shown by underline were located at the specific positions of -1, 3, and 6 from the N-terminal of the α -helix, respectively. (B) Full-length optimized nucleotide sequence of 2LTRZFP. (C) Primary sequence alignments of Aart (PDB code 2113) and 2LTRZFP with 80% sequence identity. The underlined letters represent amino acid residues of the ZFP those are different from the Aart peptide. Positions -1, 3, and 6 above the recognition helix column represent amino acid residues often involved in DNA recognition. Numbers at the end of each line show the running number of the last amino acid residue.

terminal and fused-GFP at C-terminal under the control of the CMV, T7, or p10 promoters. The plasmid vector pTriEx-4-2LTRZFP-GFP was digested by the restriction endonucleases XcmI and SmaI and the product was subjected to 1% agarose gel electrophoresis and visualized by ethidium bromide staining. Restriction digest analysis showed that the pTriEx-4-2LTRZFP-GFP was constructed successfully at a 547 bp band (data not shown).

Protein expression and purification

2LTRZFP-GFP was expressed in its recombinant forms in *E. coli* Origami B (DE3) Novagen (Madison, WI).

Protein purification was performed using His-Bind column chromatography. The entire expression and purification processes were monitored by SDS-PAGE [Fig. 3(A)]. Comparison between lane 2 [total lysate of *E. coli* Origami B (DE3)] and lane 3 [Total lysate of *E. coli* Origami B (DE3) with pTriEx-4-2LTRZFP-GFP was induced by isopropyl β -D-thiogalactopyranoside (IPTG) after OD₆₀₀ reach 1.0 at 30°C for overnight] indicates that the expression of fusion protein His6-2LTRZFP-GFP (~50 kDa) was successful. Lane 6 shows that this fusion protein bound to the His-Bind column chromatography, and it can be eluted by elution buffer containing 1M imidazole, 0.5M NaCl, 20 mM Tris-HCl, pH 7.9 (lane 7).




Figure 3. (A) SDS-PAGE analysis of His6-2LTRZFP-GFP at different and purification steps. Lane 1: protein marker, lane 2: total bacterial lysate, lane 3: total bacterial lysate with pTriEx-4-2LTRZFP-GFP after IPTG induction for overnight, lane 4: pass through lysate, lanes 5, 6: solution after washing the column with binding buffer and washing buffer, respectively, lane 7: elution of purified His6-2LTRZFP-GFP. The arrow indicates the size of 50 kDa of His6-2LTRZFP-GFP. Numbers on left show size in kilo Dalton of protein ladder. (B) Western blot analysis of His6-2LTRZFP-GFP at different condition of protein expression. Lane 1: total bacterial lysate, lanes 2, 3: total bacterial lysate with pTriEx-4-2LTRZFP-GFP after IPTG induction for 4 h, and overnight, respectively. The arrow indicates the size of 50 kDa of His6-2LTRZFP-GFP. Numbers on left show size in kilo Dalton of protein ladder.




Figure 4. Expression of green fluorescent protein in HeLa cells 24 h after transfection. (A, B) Transfected with recombinant plasmid pTriEx-4-GFP. (C, D) Transfected with recombinant plasmid pTriEx-4-2LTRZFP-GFP.

Western blotting was performed by using anti-His mAb as primary antibody [Fig. 3(B)]; the analysis demonstrated that His6-2LTRZFP-GFP (~50 KDa) was successfully expressed. To separate GFP and 2LTRZFP, the purified recombinant 2LTRZFP-GFP containing the thrombin recognition sequence was cleaved via thrombin, and 2LTRZFP was purified by using His-Bind column chromatography. (Data not shown).

Expression of 2LTRZFP-GFP in HeLa cells

To test the expression of the 2LTRZFP-GFP recombinant protein in a mammalian system, pTriEx-4-2LTRZFP-GFP was transfected into a HeLa cell line. The emitted green fluorescence was observed under the microscope 24 and 48 h after transfection. The green fluorescence was observed in the nucleus in the pTriEx-4-2LTRZFP-GFP transfection group and in the cytoplasm for pTriEx-4-GFP control group (Fig. 4). This result indicated that 2LTRZFP-GFP recombinant protein is a nuclear protein and confirmed the successful folding of the protein.

Evaluating of dissociation constants and competitive DNA binding activity by SPR

To determine real-time binding kinetics between 2LTRZFP-GFP and its target DNA sequence, we used SPR as a tool for qualitative analysis. Different concentrations of 2LTRZFP-GFP were injected into the immobilized chip with specific ds-DNA. The 2LTRZFP-GFP could bind to its target ds-DNA on a nanomolar scale, with $K_d = 12.0$ nM [Fig. 5(A)]. We also performed a competitive SPR to determine the specificity

of binding between 2LTRZFP-GFP and its target DNA. The concentration of 2LTRZFP-GFP (1.2 μ M) was used to compete with 26.5 μ M of nonbiotinylated target ds-DNA and nonspecific ds-DNA before injection onto the immobilized chip with specific ds-DNA. The 2LTRZFP-GFP could bind to its target DNA sequence [result compared with nonspecific ds-DNA, Fig. 5(B)]. In addition, the specificity of binding activity was also assayed by injection of GFP and bovine serum albumin (BSA) as controls. These results demonstrated that the binding activity was involved with ZFP only [Fig. 5(A)]. To obtain the binding properties, we also tested the binding activity of 2LTRZFP-GFP and its target DNA sequence in zinc buffer containing 1 μ M, 1 mM, and 10 mM of EDTA. The binding activity was decreased when the concentration of EDTA was high. These findings supported the conclusion that the binding between 2LTRZFP-GFP and its target DNA sequence depended on zinc ions, and that this metal ion is important for stabilizing ZFP [Fig. 5(C)].

DNA binding activity by EMSA

To confirm the binding activity, EMSA was performed using an EMSA kit as described in the section Materials and Methods. A complete binding complex of 1 μ M of 2LTRZFP-GFP and 250 nM of its specific DNA duplex could be observed [see Fig. 6(A), lane 8] until no band of free DNA duplex was seen. At the same time, a faint band of binding complex was observed in the reaction of 2LTRZFP-GFP and nonspecific DNA duplex [Fig. 6(A), lane 9], whereas the intensity of free DNA duplex was not changed [Fig. 6(A), lanes 3 and 6]. This experiment also demonstrated that GFP in




Figure 5. Kinetic analysis between 2LTRZFP-GFP and its target DNA sequence. (A) Binding kinetic of 2LTRZFP-GFP (300, 200, and 100 nM), GFP, and BSA to the immobilized chip with specific ds-DNA. (B) For the competitive SPR, 2LTRZFP-GFP was incubated with nonbiotinylated ds-DNA of its target ds-DNA, and nonspecific ds-DNA in zinc buffer for 15 min before injection. (C) 2LTRZFP-GFP was injected to determine the binding activity with its target DNA sequence in zinc buffer containing 1 μ M, 1 mM, and 10 mM of EDTA.

2LTRZFP-GFP recombinant protein was not involved in the binding [lanes 4, 5, and 6 of Fig. 6(A)]. The dilution effect of DNA binding complex can be observed in Figure 6(B,C).

2LTRZFP-DNA models and their binding energy analyses

Molecular models of the designed 2LTRZFP-DNA complexes, Zifi and Zif2, were remodeled based on the crystal structure of Aart bound to DNA (PDB code 2I13, see more details in the Materials and Methods), where all backbone atoms were maintained in the same position as found in the crystal structure. Amino acid residues within helical helices were modified solely according to our 2LTRZFP sequence [Fig. 2(C)]. Pair-wise similarity comparison between Aart and 2LTRZFP proteins was also performed using the blastp algorithm of the BLAST tool.³¹ The result showed a relatively high sequence identity (80%).




Figure 6. Electrophoretic mobility shift assay (EMSA). (A) The protein used for each reaction is 1 μ M, whereas [0], no DNA duplex; [+], specific DNA duplex; [−], nonspecific DNA duplex. The gel was stained with SYBR[®] Green EMSA stain (B) or with SYPRO[®] Ruby EMSA stain (C). In panels B and C: lanes 1 to 9, the specific DNA duplex used for each reaction was 250 nM, whereas 2LTRZFP-GFP was varied, the concentration from 0, 0.125, 0.25, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0 μ M, respectively. Lane 10, 2LTRZFP-GFP was used 3.0 μ M, but no DNA duplex.




Figure 7. Comparisons of conformation of the recognition binding region in Zif1 (in left panel) and Zif2 (in right panel). The nucleotides are shown in a licorice model and the protein backbone in a cartoon diagram.

After a 2500-cycle minimization for each of Zif1 and Zif2 complex, the root mean square deviation (RMSD) of the minimized structure of each model was measured. The RMSDs of 2LTRZFP and DNA backbones were 0.51 and 0.94 Å, respectively, suggesting that Zif1 and Zif2 are relatively similar in conformation (Fig. 7). As the first crystal structure of Zif268 bound to DNA was obtained, it has been suggested that amino acid positions -1, 3, and 6, with respect to the start of the recognition helix, play specific roles for binding to three contiguous base pairs in each DNA triplet.^{23,24} The residue-by-residue analysis of 2LTRZFP-DNA interaction for each residue in the recognition helix to each DNA triplet compared to its nonspecific triplet was subsequently explored to understand a DNA recognition pattern for 2LTRZFP.

Figure 8 demonstrates all possible hydrogen-bonding interaction between each zinc finger motif and DNA residues in both specific (Zif1) and nonspecific (Zif2) complexes, and the distances are listed in Table I. In general, a major contribution to stabilizing the 2LTRZFP-DNA complexes is the electrostatic interactions between amino acid residues in the zinc finger motif and nucleotides in the DNA target, where there is no water-mediated interaction apparent in these complexes.

In finger 1, although the hydrogen bonding network among ARG16, LYS19, and ARG22 to its DNA target in Zif1 and Zif2 is similar, the hydrogen bonds in Zif2 are weaker than those of Zif1 with respect to its longer bonding distances. The hydrogen-bond distances in finger 2 are very similar in Zif1 and Zif2, whereas they are completely different in finger 3. The amino N atom of ARG72 is bonded to the carbonyl group of DG181 in

the Zif1 complex; however, there is no hydrogen bonding between ARG72 and DC181 in Zif2 because of repulsive interaction of the positively charged amino group. The O atom of ASP74 is hydrogen bonded to the N atom of DC195 in Zif1, whereas, in Zif2, the steric effect of the methyl group in DT195 could lead to an improper formation of hydrogen bonds. A hydrogen bond donor at the amino N4 atom of DC179 (Zif1) efficiently establishes a hydrogen bond with GLU78, where the amino group of DA179 (Zif2) is located away from GLU78. Hydrogen-bond patterns in fingers 4, 5, and 6 in Zif1 and Zif2 are similar. The negatively charged amino acids, aspartic acid and glutamic acid, may play an important role in DNA recognition as being involved in selective contacts with cytosine only. Moreover, serine residues in position -2 of the recognition helices are likely to selectively bind to the phosphate backbone of the target DNA as well as arginine residues in position 6 that can bind to all bases of DNA. Finally, from the minimized structure, 2LTRZFP is more probable to establish hydrogen bonds within Zif1 than Zif2, resulting in the more selective binding to the target DNA.

In addition to the structural analysis, the molecular mechanics/generalized Born surface area (MM/GBSA) approach was used to further calculate relative binding energies between the designed peptide and the target DNA compared to its nonspecific sequence (Zif2). The $\Delta\Delta G_{\text{binding}}$ reveals that 2LTRZFP is more favorable for binding to the target DNA in Zif1 than that of Zif2 by -35.0 ± 0.5 kcal/mol (see Table II). This suggests that the Zif1 complex is mainly stabilized by the electrostatic interaction (E_{es}) as the better hydrogen-bonding network is presented.




Figure 8. Possible hydrogen bonding between the zinc finger residues and the target DNA triplet within distance < 3.5 Å^o between H-bond donor and H-bond acceptor associated with the distance.

Discussion

The Cys₂His₂ ZFPs have been demonstrated to be specific binding proteins to the recognition sequences.^{25–29} In this study, a six-finger protein was constructed specifically to 18 bp of 2-LTR-circle junctions. The first, second, and third fingers can target the terminal sequence of 5' LTR, whereas the terminal sequence of

3' LTR can be targeted by the other three fingers. The 2LTRZFP-GFP was expressed and purified from *E. coli* to investigate its binding properties. The binding activity was on the nanomolar scale, which is similar to the affinity level of HIV-1 IN.^{32,33} This finding suggested that the HIV-1 IN might be interfered with by the 2LTRZFP as well. The specificity of this binding was

Table 1. Hydrogen-Bonding Distances between 2LTRZFP Residues and DNA Residues

	2LTRZFP residue	DNA residue	Distance (Å)		2LTRZFP residue	DNA residue	Distance (Å)
Finger 1	ARG16(NH)	Zif1:DG187(O6)	2.97	Finger 4	SER99(OH)	Zif1:DT177(O2P)	2.56
		Zif2:DG187(O6)	3.29			Zif2:DT177(O2P)	2.56
	LYS19(NZ)	Zif1:DG186(O6)	2.73		GLN100(O)	Zif1:DA178(N6)	2.86
		Zif2:DA186(N6)	3.21			Zif2:DT178	–
Finger 2	ARG22(NH)	Zif1:DG185(O2P)	2.77	Finger 5	ARG106(NH)	Zif1:DG176(O6)	3.16
		Zif2:DT185(O2P)	2.74			Zif2:DC176(N4)	3.13
	SER43(OH)	Zif1:DA183(O1P)	2.66		SER127(OH)	Zif1:DC174(O2P)	2.57
		Zif2:DT183(O1P)	2.61			Zif2:DA174(O2P)	2.58
Finger 3	ASN47(ND)	Zif1:DA183(O2P)	2.80	Finger 6	ASP131(OH)	Zif1:DC174(N4)	2.95
		Zif2:DT183(O2P)	2.77			Zif2:DA174	–
	ARG50(NH)	Zif1:DG182(O6)	2.82		ARG134(NH)	Zif1:DG173(O6)	2.99
		Zif2:DA182(N6)	2.94			Zif2:DT173(O4)	2.99
Finger 3	ARG72(NH)	Zif1:DG181(O6)	2.75		SER155(OH)	Zif1:DT171(O2P)	2.57
		Zif2:DC181	–			Zif2:DG171(O2P)	2.52
	ASP74(OH)	Zif1:DC195(N4)	2.76		GLN156(NH)	Zif1:DT171(O2P)	2.82
		Zif2:DT195	–			Zif2:DG171(O2P)	2.83
Finger 3	GLU78(OH)	Zif1:DC179(N4)	2.87		GLU162(OH)	Zif1:DC170(N4)	2.85
		Zif2:DA179	–			Zif2:DT170	–

Atom names are indicated in parentheses.

Table II. Estimated Relative Binding Energies of Specific (Zif1) and Nonspecific (Zif2) Complexes from the MM/GBSA Approach

Sequence	$\Delta\Delta E_{vdw}$ (kcal mol ⁻¹)	$\Delta\Delta E_{es}$ (kcal mol ⁻¹)	$\Delta\Delta G_{pol}$ (kcal mol ⁻¹)	$\Delta\Delta G_{nonpol}$ (kcal mol ⁻¹)	$\Delta\Delta G_{binding}$ (kcal mol ⁻¹)
Zif1-Zif2	-3.1 ± 1.7	-255.9 ± 9.0	226.3 ± 8.2	-2.3 ± 0.0	-35.0 ± 0.5

obtained by competitive SPR, which indicated that there was specific binding of 2LTRZFP-GFP and its target DNA. However, this binding affinity was decreased when the concentration of EDTA in binding buffer was increased. This data demonstrated the influence of zinc ion on correct folding of 2LTRZFP domains in recognizing a specific DNA sequence. Moreover, 2LTRZFP can specifically bind to its target ds-DNA, whereas binding of GFP in the C-terminal part was not facilitated.

Additionally, theoretical studies were used to investigate at the atomic level the DNA recognition of 2LTRZFP. Although it is well known that amino acid positions -1, 3, and 6 within the recognition helix directly contact the DNA triplet, positions -2, 1, and 5 are also described as playing a role in binding to the phosphate backbone.³⁴ Our study suggests that serine at position -2 and arginine at position 6 are very important in binding to the phosphate DNA backbone and 5'-nucleotide, respectively. However, the roles of amino acid positions -1 and 3 remain unclear. The results herein are particularly interesting because single or multiple mutations of amino acid position -1 and 3 would be able to enhance selectivity of the ZFP motif to the 2-LTR-circle junctions.

Mutation of the IN enzyme encoded by *pol* gene can occur,^{18–20} while numerous studies have reported that the important 2–7 base pairs upstream and the well-conserved CA dinucleotide at the 3' end of viral cDNA play key roles in processing and strand transfer.^{35–40} Therefore, the advantage of targeting the 3'-end terminal part of HIV-1 LTR to interfere with the IN enzyme is an attractive strategy for a new approach to gene therapy.

Many investigations have targeted viral replication by ZFP recognition of the DNA of viruses. The engineered ZFPs targeting the Sp1 binding site in promoter region of HIV-1 have been reported, and one of them was found to inhibit HIV-1 replication by 75%.⁴¹ In 2004, Segal *et al.* demonstrated that a transcriptional repressor protein, namely KRAB-HLTR3, was able to achieve 100-fold repression of transcription from the HIV-1 promoter. This transcription factor also repressed the replication of several HIV-1 strains 10-to 100-fold in T-cell line and primary blood mononuclear cells with no significant cytotoxicity.⁴² Recently, ZFPs were designed to bind DNA sequences in the duck hepatitis B virus to inhibit viral transcription in tissue culture. Two candidate ZFPs decreased production of viral products and progeny viral genomes.²⁵ These studies

supported the use of ZFPs to inhibit viral replication, opening new avenues in gene therapy. There are a various methods available to deliver a protein for gene therapy. The *in vivo* adenoviral gene transfer of ZFPs has been performed to induce angiogenesis in a mouse model,⁴³ whereas retroviral and lentiviral gene transfer have been delivered the artificial zinc finger transcription factors to bind sites in the HIV-1 promoter to repress the replication of several HIV-1 strains.⁴² Recently, various nonbiological and biological carrier systems have been developed for HIV-1 gene therapy, such as nanoparticles, liposomes, or synthetic polymers, which can be taken up by many cell types.⁴⁴

Our study has demonstrated that 2LTRZFP can specifically bind to the HIV-1 integrase recognition sequence at 2-LTR-circle junctions. The findings may be applied for limiting viral integration to maximize the impact of HIV gene therapy in the future.

Materials and Methods

Zinc finger protein design

Studying order to identify target sites within the DNA sequence, the HIV-1 DNA sequence of 2-LTR-circle junctions⁴⁵ was submitted to the ZF Tools server of the Barbas Laboratory of the Scripps Research Institute.³⁰ The minimum target size of 18 base pairs was set to obtain the output DNA target sequences and amino acid sequences for the six fingers of the ZFP. This amino acid sequence was then reverse-translated into a nucleotide sequence. Codon usage of the amino acid sequences of the selected ZFP was optimized by using the JAVA Codon Adaptation Tool (JCat)⁴⁶ and by manual optimization. The designed ZFP was further modified with flanking XcmI and SmaI restriction endonuclease sites. The full-length optimized DNA sequence was sent for full-gene synthesis to Blue Heron Biotechnology (Bothell, WA). Predicted properties of the resulting proteins were computed using ExPaSy proteomics tools.⁴⁷ Prediction of protein subcellular localization was done using the LOctree program.⁴⁸

Plasmid construction

The full-length optimized DNA sequence of 2LTRZFP was synthesized and cloned into pUC19 vectors by Blue Heron Biotechnology. The 2LTRZFP gene fragment was ligated to pTriEx-4-GFP using the flanking XcmI and SmaI sites to construct pTriEx-4-2LTRZFP-

GFP, creating an N-terminal His6-fusion protein with GFP in the C-terminal part. This plasmid has a multiple expression system driven by the CMV, T7, or p10 promoters. The ligation product was transformed into the competent *E. coli* XL-1 Blue cells and plated on Luria-Bertani (LB) agar containing 100 µg/mL of ampicillin. The plasmid miniprep was performed using a QIAGEN Miniprep Kit (Qiagen, Hilden, Germany). The constructed plasmid was preliminary identified by the restriction endonucleases XcmI and SmaI. PCR and DNA sequencing were performed for confirmation.

Expression and purification of His6-2LTRZFP-GFP

We used *E. coli* Origami B (DE3) as the expression strain. A 10 mL Terrific broth preculture, supplemented with 100 µg/mL ampicillin, 12.5 µg/mL kanamycin, and 12.5 µg/mL tetracycline was incubated at 37°C until reaching an absorbance at 600 nm of about 1.0–1.8. The preculture was diluted 1:100 into 100 mL Terrific broth medium with 100 µg/mL ampicillin, 12.5 µg/mL kanamycin, 12.5 µg/mL tetracycline and supplemented with 100 µM Zn₂SO₄. The culture was incubated at 37°C. When an absorbance about 1.0 at 600 nm was reached, the bacterial culture was induced by 0.1 mM IPTG at 30°C for overnight. Bacteria were then harvested by centrifugation (7500g at 4°C for 15 min). The bacterial pellets were resuspended in 6.25 mL of B-PER II Bacterial Protein Extraction Reagent (Pierce, Rockford, IL) and lysed by ultrasonication in an ice bath. The lysate was centrifuged at 15,000g for 20 min at 4°C. The supernatant was collected and filtered with microfiltration membranes (0.22-µm pore size). The clear solution containing His6-2LTRZFP-GFP was applied to His-bind column chromatography (Novagen, San Diego, CA) for protein purification. The eluted fraction containing His6-2LTRZFP-GFP was observed using Coomassie brilliant blue R250 stain (Bio-Rad, Hercules, CA). The purified protein was kept in final concentration 25% (W/V) glycerol for long-term storage at –80°C. The protein concentration was quantified by using the Micro-BCA protein assay (Pierce). All the samples were analyzed by SDS-PAGE. Western blot analysis was performed on a Hybond-P polyvinylidene fluoride membrane. (Amersham Bioscience, Piscataway, NJ). After being blocked with 5% skim milk in PBS, the proteins were probed with anti-his-tag monoclonal antibody (Genscript, Piscataway, NJ) as a primary antibody and horseradish peroxidase-labeled goat anti-mouse (Sigma, St Louis, MO) as a secondary antibody, using the ECL system (GE Healthcare, Buckinghamshire, UK).

Cell culture and transfection of HeLa cells

HeLa cervical carcinoma cells were kindly obtained from Dr. A. Lieber, University of Washington, Seattle,

WA. HeLa cells (1×10^5) were seeded onto 24-well plate in humidified atmosphere under 5% CO₂ at 37°C in Dulbecco's Modified Eagle's medium (DMEM) (Gibco, Grand Island, NY) containing penicillin (100 U/mL), streptomycin (100 µg/mL), and 2 mM L-glutamine, supplemented with 10% fetal bovine serum (FBS) (Gibco) for 24 h before transfection. Transfection mixture was prepared by adding 1 µg of the pTriEx-4-2LTRZFP-GFP or control vector pTriEx-4-GFP and 2 µL of GeneJamer (Stratagene, La Jolla, CA) into DMEM up to 200 µL. Then, the mixture was incubated at room temperature for 10 min. The culture supernatant was discarded and 300 µL of fresh DMEM containing 10% FBS and antibiotics was added. The transfection mixture was added to the cells and incubated at 37°C in 5% CO₂ for 5 h. A total of 500 µL of DMEM containing 10% FBS and antibiotics was added and further cultured at 37°C in 5% CO₂ for 24–48 h. Green fluorescent protein (GFP) was observed under a fluorescent microscope.

Double-stranded DNA preparation

ds-DNA of specific and nonspecific target DNA was prepared for testing the binding activity of 2LTRZFP-GFP. A pair of specific ds-DNA (sense) was designed as follows: 5'-AAA TCT CTA GCA GTA CTG GAT GGG CTA ATT-3' and a pair of nonspecific ds-DNA (sense) was also designed as follows 5'-TGA CAG TGC TAG CGT ATC ATC TAG TCG ACG-3'. The specific sequences to 2LTRZFP-GFP are shown in *italic*. The reaction mixture (100 µL) for annealing was composed of each 600 pmol single-stranded DNA (ss-DNA) and complementary strand in 50 mM NaCl. The mixture was heated at 95°C for 5 min and then slowly cooled to room temperature for 90 min. For immobilization of ds-DNA on a sensor chip SA (Biacore AB, Uppsala, Sweden) for SPR, the 3' end of the antisense strand of specific target DNA was labeled with biotin.

Surface plasmon resonance

SPR was carried out on a BIACORE 2000™ biosensor (Biacore AB). The target DNA duplexes were immobilized by injecting the biotinylated specific ds-DNA of 0.5 µg/mL in 0.3M NaCl on a Sensor Chip SA (Biacore AB) at a flow rate 5 µL/min in running buffer (HBS-EP), containing 10 mM HEPES (pH 7.4), 150 mM NaCl, 3 mM EDTA, 0.005% (v/v) surfactant P20 (Biacore AB). Typically 800–1000 RUs of the target ds-DNA were immobilized. After DNA immobilization, the chip was washed with 50 mM NaOH/1M NaCl and then primed with zinc buffer [10 mM Tris-HCl, pH 7.5, 90 mM KCl, 1 mM MgCl₂, 90 µM ZnSO₄, 5 mM dithiothreitol, and 0.5 mM phenylmethylsulfonylfluoride], which was used as a running buffer for a period of binding analysis. ZFP was diluted in zinc buffer and 60 µL was injected at a flow rate of 20 µL/min, followed by a dissociation phase of 180 s. Before each injection, the baseline stability was achieved by

injecting 1M NaCl for 2 min. To calculate the binding constants (K_d), the kinetic parameters were evaluated with BIA evaluation software 3.1 (Biacore AB) using a 1:1 binding model with mass transfer. For competitive SPR, 2LTRZFP-GFP was incubated with different concentrations of nonbiotinylated ds-DNA of its target ds-DNA, and nonspecific ds-DNA in zinc buffer for 15 min before injection.

Electrophoretic mobility shift assay

2LTRZFP-GFP or GFP was incubated with 250 nM of DNA duplex at room temperature for 1 h in zinc buffer. Total volumes were 10 μ L per reaction. The reaction mixtures were mixed with 2 μ L of 6 $\times$ EMSA gel-loading solution (component D) of EMSA kit [E33075] (Invitrogen, Paisley, UK) before being loaded on 5% nondenaturing polyacrylamide gels using 100 V, 30 min. Gels were stained by using two fluorescent dyes for detection—SYBR[®] green EMSA nucleic acid gel stain (component A) and SYPRO[®] ruby EMSA protein gel stain (component B) by following the protocol from the same kit. The stained gels were imaged at an excited state of 488 nm using a Typhoon Trio phosphorImager (GE Healthcare Biosciences, Piscataway, NJ).

Molecular modeling of 2LTRZFP-DNA complexes

Construction of the 2LTRZFP-DNA complexes was initiated using an X-ray crystallographic structure of a designed six zinc finger motif (Aart) bound to an oligonucleotide from PDB entry 2I13³⁴ as a template. The sequence of the Aart peptide was then modified (using the Discovery Studio version 1.7 program package) in recognition helices according to our designed ZFP resulting from ZF Tools.³⁰ The DNA duplex from the crystal structure of the Aart-DNA complex was further remodeled to 21-mers oligonucleotides of 2-LTR-circle junctions, as follows:

5'-CTCTAGCAGTACTGGATGGGC-3'
3'-GAGATCGTCATGACCTACCCG-5' termed Zif1 as a specific complex
and
5'-AGTGCTAGCGTATCATCTAGT-3'
3'-TCACGATCGCATAGTAGATCA-5' termed Zif2 as a nonspecific complex.

All backbone atoms of the protein and DNA sequences for both modified models were maintained as in the crystal structure. The ZFP was thoroughly prepared before performing the energy calculations. Protonation states of ZF residues were decided by reassignments of all histidine residues to δ -histidine (HID) and all cysteine to CYM (cysteine with a negative charge). Finally, a longer range electrostatic model ($\sigma = 1.70$ Å, $\epsilon = 0.67$ kcal/mol) of the zinc ion (Zn^{2+})⁴⁹ was used instead of the original nonbonded zinc parameters from the AMBER force field, avoiding a disorder of the ZFP during minimizations. The Zn^{2+}

was coordinated within the ZFP by two CYM and two HID residues. A geometry with a tetrahedrally coordinated Zn^{2+} in the center of the ZFP was subsequently maintained throughout the minimizations. The remaining protein and nucleic acid parameters were determined using the AMBER ff03 force field.⁵⁰

Both Zif1 and Zif2 models were then solvated with an explicit TIP3P water model⁵¹ in a truncated octahedral box with a minimum 10 Å distance between any solute atom and a box edge. Periodic boundary conditions were applied for avoiding the impacts from the atoms on the outer surfaces drifting away from the simulation box. The systems were neutralized with a minimum number of sodium ions and were then energy minimized in two stages (only solvent and ions at first, then all atoms). Each minimization stage was performed using the first 100 steps of a steepest descent algorithm followed up with 2400 steps of conjugate gradient minimization to get closer to an energy minimum. The minimized conformations of Zif1 and Zif2 were visualized and structurally analyzed.

Analysis of the ZFP-DNA interaction energies

To investigate the relative binding energies between the designed ZFP and the target oligonucleotides, a short trajectory of each protein–DNA complex was produced. The system was treated as a ligand/receptor complex, in which the designed ZF motif was the ligand and the target DNA was the receptor. The MM/GBSA approach was then used to calculate the free energies of molecules (G_x) in solution as described in previous work⁵² [see Eqs. (1) and (2)]. The molecular mechanical energies, the van der Waals interaction (E_{vdw}), electrostatic interaction (E_{es}), and internal energy (E_{in}), as well as the free energy of the GB solvated system (G_{pol}) and the hydrophobic contribution to the solvation free energy (G_{nonpol}) were calculated with the SANDER program. The GB^{IBC} solvent model⁵³ with $\text{igb} = 2$ was used in this study. The binding energies of ZF motifs to their DNA and the relative free energies between Zif1 and Zif2 are calculated as in Eqs. (3) and (4), averaging over trajectories from the minimizations.

$$G_x = E_{\text{vdw}} + E_{\text{es}} + E_{\text{in}} + G_{\text{pol}} + G_{\text{nonpol}} \quad (1)$$

$$G_{\text{nonpol}} = 0.0072 \text{ kcal mol}^{-1} \text{Å}^{-2} \times \text{SA} \quad (2)$$

$$\Delta G_{\text{binding}} = G_{\text{complex}} - G_{\text{receptor}} - G_{\text{ligand}} \quad (3)$$

$$\Delta \Delta G_{\text{binding}} = \Delta G_{\text{binding}}(\text{Zif1}) - \Delta G_{\text{binding}}(\text{Zif2}) \quad (4)$$

Acknowledgments

The authors thank Professor Carlos F. Barbas III for providing them with EMSA kit and Associate Professor Dr. Prachya Kongtawelert for his assistance to provide the BIACORE 2000TM biosensor and NANOTEC, Thailand for the access to Discovery Studio version 1.7 program

package. They thank Dr. Dale Taneyhill for proofreading the manuscript.

References

- Mann JM, Chin J, Piot P, Quinn T (1988) The international epidemiology of AIDS. *Sci Am* 259:82–89.
- UNAIDS/World Health Organization (2008) Report on the Global HIV/AIDS Epidemic. August, Mexico City.
- Englund G, Theodore TS, Freed EO, Engelman A, Martin MA (1995) Integration is required for productive infection of monocyte-derived macrophages by human immunodeficiency virus type 1. *J Virol* 69:3216–3219.
- Engelman A, Englund G, Orenstein JM, Martin MA, Craigie R (1995) Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication. *J Virol* 69:2729–2736.
- Sakai H, Kawamura M, Sakuragi J, Sakuragi S, Shibata R, Ishimoto A, Ono N, Ueda S, Adachi A (1993) Integration is essential for efficient gene expression of human immunodeficiency virus type 1. *J Virol* 67:1169–1174.
- Swanstrom R, Delorbe WJ, Bishop JM, Varmus HE (1981) Nucleotide sequence of cloned unintegrated avian sarcoma virus DNA: viral DNA contains direct and inverted repeats similar to those in transposable elements. *Proc Natl Acad Sci USA* 78:124–128.
- Shoemaker C, Goff S, Gilboa E, Paskind M, Mitra SW, Baltimore D (1980) Structure of a cloned circular Moloney murine leukemia virus DNA molecule containing an inverted segment: implications for retrovirus integration. *Proc Natl Acad Sci USA* 77:3932–3936.
- Shank PR, Varmus HE (1978) Virus-specific DNA in the cytoplasm of avian sarcoma virus-infected cells is a precursor to covalently closed circular viral DNA in the nucleus. *J Virol* 25:104–114.
- Yoshimura FK, Weinberg RA (1979) Restriction endonuclease cleavage of linear and closed circular murine leukemia viral DNAs: discovery of a smaller circular form. *Cell* 16:323–332.
- Fritsch E, Temin HM (1977) Formation and structure of infectious DNA of spleen necrosis virus. *J Virol* 21:119–130.
- Guntaka RV, Richards OC, Shank PR, Kung HJ, Davidson N (1976) Covalently closed circular DNA of avian sarcoma virus: purification from nuclei of infected quail tumor cells and measurement by electron microscopy and gel electrophoresis. *J Mol Biol* 106:337–357.
- Gianni AM, Smotkin D, Weinberg RA (1975) Murine leukemia virus: detection of unintegrated double-stranded DNA forms of the provirus. *Proc Natl Acad Sci USA* 72:447–451.
- Vink C, Plasterk RH (1993) The human immunodeficiency virus integrase protein. *Trends Genet* 9:433–438.
- Katz RA, Skalka AM (1994) The retroviral enzymes. *Annu Rev Biochem* 63:133–173.
- De Clercq E (2001) New developments in anti-HIV chemotherapy. *Curr Med Chem* 8:1543–1572.
- Evering TH, Markowitz M (2008) Raltegravir: an integrase inhibitor for HIV-1. *Expert Opin Invest Drugs* 17:413–422.
- Grant P, Zolopa A (2008) Integrase inhibitors: a clinical review of raltegravir and elvitegravir. *J HIV Ther* 13:36–39.
- Delelis O, Malet I, Na L, Tchertanov L, Calvez V, Marcelin AG, Subra F, Deprez E, Mouscadet JF (2009) The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. *Nucleic Acids Res* 37:1193–1201.
- Hicks C, Gulick RM, Roquebert B, Blum L, Collin G, Damond F, Peytavin G, Leleu J, Matheron S, Chene G, Brun-Vezinet F, Descamps D (2009) Raltegravir: the first HIV type 1 integrase inhibitor selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen. *Clin Infect Dis* 48:931–939.
- Charpentier C, Karmochkine M, Laureillard D, Tisserand P, Belec L, Weiss L, Si-Mohamed A, Piketty C (2008) Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy. *HIV Med* 9:765–770.
- Miller J, McLachlan AD, Klug A (1985) Repetitive zinc-binding domains in the protein transcription factor IIIA from *Xenopus* oocytes. *EMBO J* 4:1609–1614.
- Lee MS, Gippert GP, Soman KV, Case DA, Wright PE (1989) Three-dimensional solution structure of a single zinc finger DNA-binding domain. *Science* 245:635–637.
- Elrod-Erickson M, Rould MA, Nekudova L, Pabo CO (1996) Zif268 protein-DNA complex refined at 1.6 Å: a model system for understanding zinc finger-DNA interactions. *Structure* 4:1171–1180.
- Pavletich NP, Pabo CO (1991) Zinc finger-DNA recognition: crystal structure of a Zif268-DNA complex at 2.1 Å. *Science* 252:809–817.
- Zimmerman KA, Fischer KP, Joyce MA, Tyrrell DL (2008) Zinc finger proteins designed to specifically target duck hepatitis B virus covalently closed circular DNA inhibit viral transcription in tissue culture. *J Virol* 82:8013–8021.
- Dreier B, Segal DJ, Barbas CF (2000) Insights into the molecular recognition of the 5'-GNN-3' family of DNA sequences by zinc finger domains. *J Mol Biol* 303:489–502.
- Dreier B, Fuller RP, Segal DJ, Lund CV, Blancafort P, Huber A, Koksche B, Barbas CF (2005) Development of zinc finger domains for recognition of the 5'-CNN-3' family DNA sequences and their use in the construction of artificial transcription factors. *J Biol Chem* 280:35588–35597.
- Dreier B, Beerli RR, Segal DJ, Flippin JD, Barbas CF (2001) Development of zinc finger domains for recognition of the 5'-ANN-3' family of DNA sequences and their use in the construction of artificial transcription factors. *J Biol Chem* 276:29466–29478.
- Blancafort P, Segal DJ, Barbas CF (2004) Designing transcription factor architectures for drug discovery. *Mol Pharmacol* 66:1361–1371.
- Mandell JG, Barbas CF (2006) Zinc finger tools: custom DNA-binding domains for transcription factors and nucleases. *Nucleic Acids Res* 34:W516–W523.
- Altschul SF, Madden TL, Schäffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ (1997) Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. *Nucleic Acids Res* 25:3389–3402.
- Deprez E, Barbe S, Kolaski M, Leh H, Zouhiri F, Auclair C, Brochon JC, Le Bret M, Mouscadet JF (2004) Mechanism of HIV-1 integrase inhibition by styrylquinoline derivatives in vitro. *Mol Pharmacol* 65:85–98.
- Bugreev DV, Baranova S, Zakharova OD, Parissi V, Desjobert C, Sottofattori E, Balbi A, Litvak S, Tarrago-Litvak L, Nevinsky GA (2003) Dynamic, thermodynamic, and kinetic basis for recognition and transformation of DNA by human immunodeficiency virus type 1 integrase. *Biochemistry* 42:9235–9247.
- Segal DJ, Crotty JW, Bhakta MS, Barbas CF, Horton NC, Mandell JG, Eberhardy SR, Goncalves J, Coelho S, Berkhout B, Dreier B, Fuller R, Lund CV, Blancafort P, Huber A, Koksche B (2006) Structure of Aart, a

- designed six-finger zinc finger peptide, bound to DNA. *J Mol Biol* 363:405–421.
35. Balakrishnan M, Jonsson CB (1997) Functional identification of nucleotides conferring substrate specificity to retroviral integrase reactions. *J Virol* 71:1025–1035.
 36. Katzman M, Sudol M (1996) Influence of subterminal viral DNA nucleotides on differential susceptibility to cleavage by human immunodeficiency virus type 1 and visna virus integrases. *J Virol* 70:9069–9073.
 37. Yoshinaga T, Fujiwara T (1995) Different roles of bases within the integration signal sequence of human immunodeficiency virus type 1 in vitro. *J Virol* 69:3233–3236.
 38. Van den Ent FM, Vink C, Plasterk RH (1994) DNA substrate requirements for different activities of the human immunodeficiency virus type 1 integrase protein. *J Virol* 68:7825–7832.
 39. Vink C, Van Gent DC, Elgersma Y, Plasterk RH (1991) Human immunodeficiency virus integrase protein requires a subterminal position of its viral DNA recognition sequence for efficient cleavage. *J Virol* 65:4636–4644.
 40. Lafemina RL, Callahan PL, Cordingley MG (1991) Substrate specificity of recombinant human immunodeficiency virus integrase protein. *J Virol* 65:5624–5630.
 41. Reynolds L, Ullman C, Moore M, Isalan M, West MJ, Clapham P, Klug A, Choo Y (2003) Repression of the HIV-1 5' LTR promoter and inhibition of HIV-1 replication by using engineered zinc-finger transcription factors. *Proc Natl Acad Sci USA* 100:1615–1620.
 42. Segal DJ, Goncalves J, Eberhardy S, Swan CH, Torbett BE, Li X, Barbas CF (2004) Attenuation of HIV-1 replication in primary human cells with a designed zinc finger transcription factor. *J Biol Chem* 279:14509–14519.
 43. Rebar EJ, Huang Y, Hickey R, Nath AK, Meoli D, Nath S, Chen B, Xu L, Liang Y, Jamieson AC, Zhang L, Spratt SK, Case CC, Wolfe A, Giordano FJ (2002) Induction of angiogenesis in a mouse model using engineered transcription factors. *Nat Med* 8:1427–1432.
 44. Lanao JM, Briones E, Colino CI (2007) Recent advances in delivery systems for anti-HIV1 therapy. *J Drug Target* 15:21–36.
 45. Whitcomb JM, Kumar R, Hughes SH (1990) Sequence of the circle junction of human immunodeficiency virus type 1: implications for reverse transcription and integration. *J Virol* 64:4903–4906.
 46. Grote A, Hiller K, Scheer M, Munch R, Nortemann B, Hempel DC, Jahn D (2005) JCat: a novel tool to adapt codon usage of a target gene to its potential expression host. *Nucleic Acids Res* 33:W526–W531.
 47. Wilkins MR, Gasteiger E, Bairoch A, Sanchez JC, Williams KL, Appel RD, Hochstrasser DF (1999) Protein identification and analysis tools in the ExPASy server. *Methods Mol Biol* 112:531–552.
 48. Nair R, Rost B (2005) Mimicking cellular sorting improves prediction of subcellular localization. *J Mol Biol* 348:85–100.
 49. Stote RH, Karplus M (1995) Zinc binding in proteins and solution: a simple but accurate nonbonded representation. *Proteins* 23:12–31.
 50. Duan Y, Wu C, Chowdhury S, Lee MC, Xiong G, Zhang W, Yang R, Cieplak P, Luo R, Lee T, Caldwell J, Wang J, Kollman P (2003) A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. *J Comput Chem* 24:1999–2012.
 51. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML (1983) Comparison of simple potential functions for simulating liquid water. *J Chem Phys* 79:926–935.
 52. Jiranusornkul S, Laughton CA (2008) Destabilization of DNA duplexes by oxidative damage at guanine: implications for lesion recognition and repair. *J R Soc Interface* 5 (Suppl 3):S191–S198.
 53. Onufriev A, Bashford D, Case DA (2000) Modification of the generalized Born model suitable for macromolecules. *J Phys Chem B* 104:3712–3720.

Zinc Finger Protein Designed to Target 2-LTR Junctions Interferes with HIV Integration

Supachai Sakkhachornphop,^{1,2} Carlos F. Barbas III,³ Rassamee Keawvichit,² Kanlaya Wongworapat,² and Chatchai Tayapiwatana^{1,4}

¹Division of Clinical Immunology, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, 50200, Thailand.

²Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, 50200, Thailand.

³The Skaggs Institute for Chemical Biology and the Departments of Molecular Biology and Chemistry, the Scripps Research Institute, La Jolla, California, 92037.

⁴Biomedical Technology Research Unit, National Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency at the Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, 50200, Thailand.

Address correspondence to:

Dr. Chatchai Tayapiwatana

Division of Clinical Immunology

Department of Medical Technology

Faculty of Associated Medical Sciences

Chiang Mai University, Chiang Mai 50200, Thailand

Phone: (66) 5394-5070. Fax: (66) 5394-6042

E-mail: chatchai.t@cmu.ac.th

Running title: Inhibition of HIV-1 integration by ZFP



Abstract

Integration of the human immunodeficiency virus type 1 (HIV-1) genome into the host chromosome is a vital step in the HIV life cycle. The highly conserved cytosine-adenine (CA) dinucleotide sequence immediately upstream of the cleavage site is crucial for integrase (IN) activity. As this viral enzyme has an important role early in the HIV-1 replication cycle, interference with the IN substrate has become an attractive strategy for therapeutic intervention. Recently, we demonstrated that a designed zinc finger protein (ZFP) fused to green fluorescent protein (GFP) targets the 2-long terminal repeat circle junctions of HIV-1 DNA with nanomolar affinity. We report now that 2LTRZFP-GFP stably transduced into 293T cells interfered with the expression of vesicular stomatitis virus glycoprotein (VSV-G)-pseudotyped lentiviral red fluorescent protein (RFP), as shown by the suppression of RFP expression. We also used a third-generation lentiviral vector and pCEP4 expression vector to deliver the 2LTRZFP-GFP transgene into human T-lymphocytic cells, and a stable cell line for long-term expression studies was selected for HIV-1 challenge. HIV-1 integration and replication were inhibited as measured by *Alu-gag* real-time PCR and p24 antigen assay. In addition, the molecular activity of 2LTRZFP-GFP was evaluated in peripheral blood mononuclear cells (PBMCs). The results were confirmed with *Alu-gag* real-time PCR for integration interferences. We address that the expression of 2LTRZFP-GFP limited viral integration upon intracellular immunisation, and it has potential for use in HIV gene therapy in the future.

